Exact Mass: 383.1764

Exact Mass Matches: 383.1764

Found 500 metabolites which its exact mass value is equals to given mass value 383.1764, within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error 0.01 dalton.

N-Acetyllactosamine

N-[(2R,3R,4R,5S,6R)-2,4-dihydroxy-6-(hydroxymethyl)-5-{[(2S,3R,4S,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}oxan-3-yl]acetamide

C14H25NO11 (383.1428)


N-Acetyllactosamine, also known as galb1-4glcnacb or lacnac, belongs to the class of organic compounds known as acylaminosugars. These are organic compounds containing a sugar linked to a chain through N-acyl group. N-Acetyllactosamine exists in all living organisms, ranging from bacteria to humans. Structural unit in higher oligosaccharides present in human milk N-Acetyllactosamine (LacNAc), a nitrogen-containing disaccharide, is an important component of various oligosaccharides such as glycoproteins and sialyl Lewis X. N-Acetyllactosamine can be used as the starting material for the synthesis of various oligosaccharides. N-Acetyllactosamine has prebiotic effects[1][2].

   

Prazosin

1-(4-Amino-6,7-dimethoxy-2-quinazolinyl)-4-(2-furanylcarbonyl)piperazine

C19H21N5O4 (383.1593)


Prazosin is a selective α-1-adrenergic receptor antagonist used to treat hypertension. It has also been used to decrease urinary obstruction and relieve symptoms associated with symptomatic benign prostatic hyperplasia. α1-Receptors mediate contraction and hypertrophic growth of smooth muscle cells. Antagonism of these receptors leads to smooth muscle relaxation in the peripheral vasculature and prostate gland. Prazosin has also been used in conjunction with cardiac glycosides and diuretics in the management of severe congestive heart failure. It has also been used alone or in combination with β-blockers in the preoperative management of signs and symptoms of pheochromocytoma. C - Cardiovascular system > C02 - Antihypertensives > C02C - Antiadrenergic agents, peripherally acting > C02CA - Alpha-adrenoreceptor antagonists C78272 - Agent Affecting Nervous System > C29747 - Adrenergic Agent > C72900 - Adrenergic Antagonist D018377 - Neurotransmitter Agents > D018663 - Adrenergic Agents > D018674 - Adrenergic Antagonists C78274 - Agent Affecting Cardiovascular System > C270 - Antihypertensive Agent COVID info from clinicaltrial, clinicaltrials, clinical trial, clinical trials D002317 - Cardiovascular Agents > D000959 - Antihypertensive Agents KEIO_ID P191; [MS2] KO009165 Corona-virus KEIO_ID P191 Coronavirus SARS-CoV-2 COVID-19 SARS-CoV COVID19 SARS2 SARS Prazosin is an alpha-adrenergic blocker and is a sympatholytic drug used to treat high blood pressure and anxiety, PTSD, and panic disorder. Target: Adrenergic Receptor Prazosin, is a sympatholytic drug used to treat high blood pressure and anxiety, PTSD, andpanic disorder. It is an alpha-adrenergic blocker that is specific for the alpha-1 receptors. These receptors are found on vascular smooth muscle, where they are responsible for the vasoconstrictive action of norepinephrine. They are also found throughout the central nervous system. As of 2013, prazosin is off-patent in the US, and the FDA has approved at least one generic manufacturer.In addition to its alpha-blocking activity, prazosin is an antagonist of the MT3 receptor (which is not present in humans), with selectivity for this receptor over the MT1 and MT2 receptors. Prazosin is orally active and has a minimal effect on cardiac function due to its alpha-1 receptor selectivity. However, when prazosin is initially started, heart rate and contractility go up in order to maintain the pre-treatment blood pressures because the body has reached homeostasis at its abnormally high blood pressure. The blood pressure lowering effect becomes apparent when prazosin is taken for longer periods of time. The heart rate and contractility go back down over time and blood pressure decreases.

   

Quetiapine

2-[2-(4-{2-thia-9-azatricyclo[9.4.0.0³,⁸]pentadeca-1(15),3,5,7,9,11,13-heptaen-10-yl}piperazin-1-yl)ethoxy]ethan-1-ol

C21H25N3O2S (383.1667)


The most common side effect is sedation, and is prescribed specifically for this effect in patients with sleep disorders. Seroquel will put the patient into a drowsy state, and will help the patient fall asleep. It is one of the most sedating of all anti psychotic drugs, rivaling even the most sedating older antipsychotics. Many prescriptions call for the entire dose to be taken before bedtime because of its sedative effects. Although quetiapine is approved by the FDA for the treatment of schizophrenia and bipolar disorder, it is frequently prescribed for off-label purposes including insomnia or the treatment of anxiety disorders. Due to its sedative side effects, reports of quetiapine abuse (sometimes by insufflating crushed tablets) have emerged in medical literature; Quetiapine belongs to a series of neuroleptics known as "atypical antipsychotics", which have become increasingly popular alternatives to "typical antipsychotics" such as haloperidol. Quetiapine HAS approvals for the treatment of schizophrenia and acute mania in bipolar disorder. It is also used off-label to treat other disorders, such as post-traumatic stress disorder, alcoholism, obsessive compulsive disorder, anxiety disorders, hallucinations in Parkinsons disease patients using ropinirole, and as a sedative for those with sleep disorders. The most common side effect is sedation, and is prescribed specifically for this effect in patients with sleep disorders. Seroquel will put the patient into a drowsy state, and will help the patient fall asleep. It is one of the most sedating of all anti psychotic drugs, rivaling even the most sedating older antipsychotics. Many prescriptions call for the entire dose to be taken before bedtime because of its sedative effects. Although quetiapine is approved by the FDA for the treatment of schizophrenia and bipolar disorder, it is frequently prescribed for off-label purposes including insomnia or the treatment of anxiety disorders. Due to its sedative side effects, reports of quetiapine abuse (sometimes by insufflating crushed tablets) have emerged in medical literature; for the same reason, abuse of other antipsychotics, such as chlorpromazine (Thorazine), may occur as well, but research related to the abuse of typical antipsychotics is limited. for the same reason, abuse of other antipsychotics, such as chlorpromazine (Thorazine), may occur as well, but research related to the abuse of typical antipsychotics is limited. The most common side effect is sedation, and is prescribed specifically for this effect in patients with sleep disorders. Seroquel will put the patient into a drowsy state, and will help the patient fall asleep. It is one of the most sedating of all anti psychotic drugs, rivaling even the most sedating older antipsychotics. Many prescriptions call for the entire dose to be taken before bedtime because of its sedative effects. Although quetiapine is approved by the FDA for the treatment of schizophrenia and bipolar disorder, it is frequently prescribed for off-label purposes including insomnia or the treatment of anxiety disorders. Due to its sedative side effects, reports of quetiapine abuse (sometimes by insufflating crushed tablets) have emerged in medical literature; Quetiapine belongs to a series of neuroleptics known as "atypical antipsychotics", which have become increasingly popular alternatives to "typical antipsychotics" such as haloperidol. N - Nervous system > N05 - Psycholeptics > N05A - Antipsychotics > N05AH - Diazepines, oxazepines, thiazepines and oxepines D002492 - Central Nervous System Depressants > D014149 - Tranquilizing Agents > D014150 - Antipsychotic Agents D002491 - Central Nervous System Agents > D011619 - Psychotropic Drugs > D000928 - Antidepressive Agents D002491 - Central Nervous System Agents > D011619 - Psychotropic Drugs > D014149 - Tranquilizing Agents D002491 - Central Nervous System Agents > D002492 - Central Nervous System Depressants COVID info from clinicaltrial, clinicaltrials, clinical trial, clinical trials C78272 - Agent Affecting Nervous System > C66885 - Serotonin Antagonist C78272 - Agent Affecting Nervous System > C29710 - Antipsychotic Agent Corona-virus Coronavirus SARS-CoV-2 COVID-19 SARS-CoV COVID19 SARS2 SARS Quetiapine (ICI204636) is a 5-HT receptors agonist with a pEC50 of 4.77 for human 5-HT1A receptor. Quetiapine is a dopamine receptor antagonist with a pIC50 of 6.33 for human D2 receptor. Quetiapine has moderate to high affinity for the human D2, HT1A, 5-HT2A, 5-HT2C receptor with pKis of 7.25, 5.74, 7.54, 5.55. Antidepressant and anxiolytic effects[1].

   

Lacto-N-biose I

N-[(2S,3R,4R,5S,6R)-2,5-Dihydroxy-6-(hydroxymethyl)-4-{[(2R,3R,4S,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}oxan-3-yl]ethanimidate

C14H25NO11 (383.1428)


Lacto-N-biose I is a common oligosaccharide found in human milk and in numerous other tissues. Oligosaccharides are important components of glycoproteins and glycolipids and also occur as free oligosaccharides in several body fluids.(PMID: 14993226; 11925506; 11432777; 9760191; 9592127; 8608564; 7591266; 7627975; 7766648; 1490103; 3146987; 6689405) [HMDB] Lacto-N-biose I is a common oligosaccharide found in human milk and in numerous other tissues. Oligosaccharides are important components of glycoproteins and glycolipids and also occur as free oligosaccharides in several body fluids.(PMID: 14993226; 11925506; 11432777; 9760191; 9592127; 8608564; 7591266; 7627975; 7766648; 1490103; 3146987; 6689405).

   

Dihydrozeatin-O-glucoside

(2R,3S,4S,5R,6R)-2-(hydroxymethyl)-6-[(2S)-2-methyl-4-[(3H-purin-6-yl)amino]butoxy]oxane-3,4,5-triol

C16H25N5O6 (383.1805)


Dihydrozeatin-O-glucoside belongs to the class of organic compounds known as fatty acyl glycosides of mono- and disaccharides. Fatty acyl glycosides of mono- and disaccharides are compounds composed of a mono- or disaccharide moiety linked to one hydroxyl group of a fatty alcohol, a phosphorylated alcohol (phosphoprenol), or a hydroxy fatty acid, or to one carboxyl group of a fatty acid (ester linkage) or an amino alcohol. Dihydrozeatin-O-glucoside is an extremely weak basic (essentially neutral) compound (based on its pKa). Dihydrozeatin-O-glucoside is the product of the O-glucosylation of dihydrozeatin in the cytokinin O-glucosylation. The O-glucosylation is reversible and resistant to beta-glucosidases. This reaction only shuts the physiological activity of the molecule temporarily, and is a way to store a molecule. A human metabolite taken as a putative food compound of mammalian origin [HMDB]. Dihydrozeatin-O-glucoside is found in many foods, some of which are tarragon, swede, mamey sapote, and oil-seed camellia.

   

1-Adgmi

1-O-[2-(Acetylamino)-2-deoxy-alpha-D-glucopyranosyl]-D-myo-Inositol

C14H25NO11 (383.1428)


   

7-Methylthioheptyl-desulfoglucosinolate

7-(methylsulfanyl)heptyl-desulfoglucosinolate

C15H29NO6S2 (383.1436)


   

Deoxyaureothin

Deoxyaureothin

C22H25NO5 (383.1733)


A 4-pyranone that is 2-methoxy-3,5-dimethyl-4H-pyran-4-one which is substituted at position 6 by a 2,4-dimethyl-1-(p-nitrophenyl)hexa-1,3-dien-6-yl group (the E,E isomer).

   

β-D-Galp-(1→3)-D-GalpNAc

beta-D-Galp-(1->3)-D-GalpNAc

C14H25NO11 (383.1428)


An amino disaccharide consisting of D-galactopyranose at the non-reducing end joined by a (1->3) glycosidic linkage to N-acetyl-beta-D-galactopyranose.

   

4-O-beta-D-Mannopyranosyl-N-acetyl-D-glucosamine

4-O-beta-D-Mannopyranosyl-N-acetyl-D-glucosamine

C14H25NO11 (383.1428)


   

Sacubitrilat

Sacubitrilat

C22H25NO5 (383.1733)


C78274 - Agent Affecting Cardiovascular System > C270 - Antihypertensive Agent

   

Meropenem

Meropenem

C17H25N3O5S (383.1515)


J - Antiinfectives for systemic use > J01 - Antibacterials for systemic use > J01D - Other beta-lactam antibacterials > J01DH - Carbapenems D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D013845 - Thienamycins D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D047090 - beta-Lactams D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D007769 - Lactams C254 - Anti-Infective Agent > C258 - Antibiotic > C260 - Beta-Lactam Antibiotic Meropenem (SM 7338) is a carbapenem antibiotic with broad-spectrum antibacterial activity. Meropenem has activity against susceptible and resistant N. gonorrhoeae (MIC value of 0.02-0.06 mg/mL), H. influenzae (MIC value of 0.03-0.12 mg/mL), and H. ducreyi (MIC value of 0.015-0.12 mg/mL)[1][2].

   

Dihydrozeatin-9-N-glucoside

(2R,3R,4S,5S,6R)-2-(6-{[(3S)-4-hydroxy-3-methylbutyl]amino}-9H-purin-9-yl)-6-(hydroxymethyl)oxane-3,4,5-triol

C16H25N5O6 (383.1805)


Dihydrozeatin-9-N-glucoside belongs to the class of organic compounds known as glycosylamines. Glycosylamines are compounds consisting of an amine with a beta-N-glycosidic bond to a carbohydrate, thus forming a cyclic hemiaminal ether bond (alpha-amino ether). Dihydrozeatin-9-N-glucoside is possibly neutral. Dihydrozeatin-9-N-glucoside is involved in cytokinin 9-N-glucoside biosynthesis and is also involved in cytokinin-O-glucoside biosynthesis as a precursor to dihydrozeatin-9-N-glucoside-O-glucoside. N-Glucosylation at the 9-position is similar to the N-glucosylation at the 7-position. A human metabolite taken as a putative food compound of mammalian origin [HMDB]. Dihydrozeatin-9-N-glucoside is found in many foods, some of which are tronchuda cabbage, pear, persian lime, and turmeric.

   

Niazimin

(2S,3R,4S,5R,6S)-6-(4-{[(ethoxycarbonyl)amino]methyl}phenoxy)-4,5-dihydroxy-2-methyloxan-3-yl acetate

C18H25NO8 (383.158)


Niazimin is a glucosinolate and a naturally occurring carbamate. It has been isolated from the leaves of Moringa oleifera (horseradish tree). It is found in fats and oils, herbs and spices, and green vegetables. The cis and trans rotamers of niazimin (niazimin A and niazimin B, respectively) differ in the orientation of the NH group with respect to the carbonyl group. Constituent of Moringa oleifera (horseradish tree). Niazimin A is found in fats and oils, herbs and spices, and green vegetables.

   

Poly-N-acetyllactosamine

N-[(2R,3R,4S,5R)-3,5,6-Trihydroxy-1-oxo-4-{[(2S,3R,4S,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}hexan-2-yl]ethanimidate

C14H25NO11 (383.1428)


Poly-N-acetyllactosamine is a unique carbohydrate composed of N-acetyllactosamine repeats. In particular, poly-N-acetyllactosamine chains are synthesized by repeated alternating additions of N-acetylglucosamine and galactose, catalyzed by -1,3-N-acetylglucosaminyltransferases (poly-N-acetyllactosamine synthase) and -1,4-galactosyltransferases. What is depicted and described in this MetaboCard is a single subunit structure. Poly-N-acetyllactosamine structures occur in mammalian glycoproteins in both N- and O-linked glycans. They represent a backbone for additional modifications by fucosyltransferases, sialyltransferases and sulfotransferases. These glycans have been suggested to be involved in biospecific interactions with selectins and other glycan-binding proteins. Moreover, the poly-Nacetyllactosamine chains in N-glycans have been found to promote tumor progression and metastasis (PMID: 12570780) [HMDB] Poly-N-acetyllactosamine is a unique carbohydrate composed of N-acetyllactosamine repeats. In particular, poly-N-acetyllactosamine chains are synthesized by repeated alternating additions of N-acetylglucosamine and galactose, catalyzed by -1,3-N-acetylglucosaminyltransferases (poly-N-acetyllactosamine synthase) and -1,4-galactosyltransferases. What is depicted and described in this MetaboCard is a single subunit structure. Poly-N-acetyllactosamine structures occur in mammalian glycoproteins in both N- and O-linked glycans. They represent a backbone for additional modifications by fucosyltransferases, sialyltransferases and sulfotransferases. These glycans have been suggested to be involved in biospecific interactions with selectins and other glycan-binding proteins. Moreover, the poly-Nacetyllactosamine chains in N-glycans have been found to promote tumor progression and metastasis (PMID: 12570780).

   

Dihydrozeatin-7-N-glucoside

(2R,3R,4S,5S,6R)-2-(6-{[(3S)-4-hydroxy-3-methylbutyl]amino}-7H-purin-7-yl)-6-(hydroxymethyl)oxane-3,4,5-triol

C16H25N5O6 (383.1805)


Dihydrozeatin-7-N-glucoside (CAS: 91599-03-0) belongs to the class of organic compounds known as glycosylamines. Glycosylamines are compounds consisting of an amine with a beta-N-glycosidic bond to a carbohydrate, thus forming a cyclic hemiaminal ether bond (alpha-amino ether). Dihydrozeatin-7-N-glucoside is a strong basic compound (based on its pKa). Dihydrozeatin-7-N-glucoside is involved in cytokinin 7-N glucoside biosynthesis in plants as a product of the N-glucosylation of dihydrozeatin by UDP-glucose. When plants are exposed to a high concentration of cytokinins many are conjugated into 7-N glucosides. The addition to the N position decreases the physiological activity of the cytokine. Therefore, N-glucosylation may be a strategy of detoxification for plants. N-Glucosylation is common in radish.

   

beta-1,4-Mannosyl-N-acetylglucosamine

N-[(2R,3R,4R,5S,6R)-2,4-dihydroxy-6-(hydroxymethyl)-5-{[(2S,3S,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}oxan-3-yl]acetamide

C14H25NO11 (383.1428)


beta-1,4-Mannosyl-N-acetylglucosamine, also known as 4-O-beta-D-Mannopyranosyl-N-acetyl-D-glucosamine or Man(β1-4)GlcNAc, is an intermediate in aminosugar metabolism. It is a substrate of lysosomal beta-mannosidase.

   

Meropenem

(4R,5S,6S)-3-{[(3S,5S)-5-(dimethylcarbamoyl)pyrrolidin-3-yl]sulfanyl}-6-[(1R)-1-hydroxyethyl]-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid

C17H25N3O5S (383.1515)


Meropenem is only found in individuals that have used or taken this drug.It is a broad-spectrum carbapenem antibiotic. It is active against Gram-positive and Gram-negative bacteria. The bactericidal activity of meropenem results from the inhibition of cell wall synthesis. Meropenem readily penetrates the cell wall of most Gram-positive and Gram-negative bacteria to reach penicillin-binding- protein (PBP) targets and interfere with the synthesis of the vital cell wall components, which leads to cell death. Its strongest affinities are toward PBPs 2, 3 and 4 of Escherichia coli and Pseudomonas aeruginosa; and PBPs 1, 2 and 4 of Staphylococcus aureus. J - Antiinfectives for systemic use > J01 - Antibacterials for systemic use > J01D - Other beta-lactam antibacterials > J01DH - Carbapenems D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D013845 - Thienamycins D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D047090 - beta-Lactams D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D007769 - Lactams C254 - Anti-Infective Agent > C258 - Antibiotic > C260 - Beta-Lactam Antibiotic Meropenem (SM 7338) is a carbapenem antibiotic with broad-spectrum antibacterial activity. Meropenem has activity against susceptible and resistant N. gonorrhoeae (MIC value of 0.02-0.06 mg/mL), H. influenzae (MIC value of 0.03-0.12 mg/mL), and H. ducreyi (MIC value of 0.015-0.12 mg/mL)[1][2].

   

N-[(2R,3R,4R,5R)-3,5,6-Trihydroxy-1-oxo-4-[(2R,3R,4S,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyhexan-2-yl]acetamide

N-[(2R,3R,4R,5R)-3,5,6-Trihydroxy-1-oxo-4-[(2R,3R,4S,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyhexan-2-yl]acetamide

C14H25NO11 (383.1428)


   

3-[5-(Dimethylcarbamoyl)pyrrolidin-3-yl]sulfanyl-6-(1-hydroxyethyl)-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid

3-{[5-(dimethylcarbamoyl)pyrrolidin-3-yl]sulphanyl}-6-(1-hydroxyethyl)-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid

C17H25N3O5S (383.1515)


   

N-[(1R)-2,3-Dihydro-1H-inden-1-yl]-adenosine

2-{6-[(2,3-dihydro-1H-inden-1-yl)amino]-9H-purin-9-yl}-5-(hydroxymethyl)oxolane-3,4-diol

C19H21N5O4 (383.1593)


   

Anagliptin

N-(2-{[2-(2-cyanopyrrolidin-1-yl)-2-oxoethyl]amino}-2-methylpropyl)-2-methylpyrazolo[1,5-a]pyrimidine-6-carboxamide

C19H25N7O2 (383.207)


   

L-Proline, 1-(N-((3-((propylamino)carbonyl)oxiranyl)carbonyl)-L-isoleucyl)-, (2S-trans)-

1-((S)-3-Methyl-2-(((2S,3S)-3-propylcarbamoyl-oxiranecarbonyl)-amino)-pentanoyl)-pyrrolidine-2-carboxylic acid

C18H29N3O6 (383.2056)


   

3-((2'-Carboxybiphenyl-4-yl)methyl)-2-cyclopropyl-7-methyl-3H-imidazo(4,5-b)pyridine

4-({2-cyclopropyl-7-methyl-3H-imidazo[4,5-b]pyridin-3-yl}methyl)-[1,1-biphenyl]-2-carboxylic acid

C24H21N3O2 (383.1634)


   

Galbeta1-3GIcNAcbeta

N-[2,5-Dihydroxy-6-(hydroxymethyl)-4-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}oxan-3-yl]ethanimidate

C14H25NO11 (383.1428)


   

LEUCOGENENOL

2-(1,2-dihydroxy-3-methyl-5-oxocyclohexyl)-3,11-dihydroxy-11-(hydroxymethyl)-9-methyl-1-oxa-5-azaspiro[5.5]undeca-2,4-dien-7-one

C18H25NO8 (383.158)


   

Losmapimod

6-(5-((cyclopropylamino)Carbonyl)-3-fluoro-2-methylphenyl)-N-(2,2-dimethylprpyl)-3-pyridinecarboxamide

C22H26FN3O2 (383.2009)


C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C2149 - Mitogen-Activated Protein Kinase Inhibitor C471 - Enzyme Inhibitor > C1404 - Protein Kinase Inhibitor > C61074 - Serine/Threonine Kinase Inhibitor COVID info from clinicaltrial, clinicaltrials, clinical trial, clinical trials Corona-virus Coronavirus SARS-CoV-2 COVID-19 SARS-CoV COVID19 SARS2 SARS

   

Methyl (1-(4-fluorobenzyl)-1H-indazole-3-carbonyl)-L-valinate

methyl 2-({1-[(4-fluorophenyl)methyl]-1H-indazol-3-yl}formamido)-3-methylbutanoate

C21H22FN3O3 (383.1645)


   

Propiverine N-oxide

4-[(2,2-diphenyl-2-propoxyacetyl)oxy]-1-methylpiperidin-1-ium-1-olate

C23H29NO4 (383.2096)


   

Sacubitrilat

5-{[1,1-biphenyl]-4-yl}-4-[(3-carboxy-1-hydroxypropylidene)amino]-2-methylpentanoate

C22H25NO5 (383.1733)


   

Thomsen-friedenreich antigen

N-(4,5,6-Trihydroxy-1-oxo-3-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}hexan-2-yl)ethanimidate

C14H25NO11 (383.1428)


   

VERALIPRIDE

2,3-Dimethoxy-N-{[1-(prop-2-en-1-yl)pyrrolidin-2-yl]methyl}-5-sulphamoylbenzene-1-carboximidic acid

C17H25N3O5S (383.1515)


D002492 - Central Nervous System Depressants > D014149 - Tranquilizing Agents > D014150 - Antipsychotic Agents D002491 - Central Nervous System Agents > D011619 - Psychotropic Drugs > D014149 - Tranquilizing Agents D002491 - Central Nervous System Agents > D002492 - Central Nervous System Depressants N - Nervous system > N05 - Psycholeptics > N05A - Antipsychotics > N05AL - Benzamides C78272 - Agent Affecting Nervous System > C66883 - Dopamine Antagonist Veralipride is a D2 receptor antagonist. It is an alternative antidopaminergic treatment for menopausal symptoms.

   

N'-[2-(Oxidanylcarbamoyl)phenyl]-N-phenyl-octanediamide

N-[2-(dihydroxycarbonimidoyl)phenyl]-N-phenyloctanediimidate

C21H25N3O4 (383.1845)


   

Dihydrozeatin O-beta-D-Glucoside

2-(hydroxymethyl)-6-{2-methyl-4-[(7H-purin-6-yl)amino]butoxy}oxane-3,4,5-triol

C16H25N5O6 (383.1805)


Dihydrozeatin o-beta-d-glucoside is a member of the class of compounds known as fatty acyl glycosides of mono- and disaccharides. Fatty acyl glycosides of mono- and disaccharides are compounds composed of a mono- or disaccharide moiety linked to one hydroxyl group of a fatty alcohol or of a phosphorylated alcohol (phosphoprenols), a hydroxy fatty acid or to one carboxyl group of a fatty acid (ester linkage) or to an amino alcohol. Dihydrozeatin o-beta-d-glucoside is slightly soluble (in water) and a very weakly acidic compound (based on its pKa). Dihydrozeatin o-beta-d-glucoside can be found in soy bean, which makes dihydrozeatin o-beta-d-glucoside a potential biomarker for the consumption of this food product.

   

Niazimin A

N-[(4-{[5-(acetyloxy)-3,4-dihydroxy-6-methyloxan-2-yl]oxy}phenyl)methyl]ethoxycarboximidate

C18H25NO8 (383.158)


Constituent of Moringa oleifera (horseradish tree). Niazimin A is found in fats and oils, herbs and spices, and green vegetables.

   

7-methylthioheptyldesulfoglucosinolate

2-{[1-(hydroxyimino)-8-(methylsulphanyl)octyl]sulphanyl}-6-(hydroxymethyl)oxane-3,4,5-triol

C15H29NO6S2 (383.1436)


7-methylthioheptyldesulfoglucosinolate is slightly soluble (in water) and a very weakly acidic compound (based on its pKa). 7-methylthioheptyldesulfoglucosinolate can be found in a number of food items such as brassicas, alpine sweetvetch, prunus (cherry, plum), and greenthread tea, which makes 7-methylthioheptyldesulfoglucosinolate a potential biomarker for the consumption of these food products.

   

SCHEMBL13131860

SCHEMBL13131860

C22H25NO5 (383.1733)


   

Neocarazostatin C

Neocarazostatin C

C23H29NO4 (383.2096)


   

Dehydrothalicsimidine

Dehydrothalicsimidine

C22H25NO5 (383.1733)


   

Antibiotic BN 186B

Antibiotic BN 186B

C14H29N3O9 (383.1904)


   
   

(+)-trans-Erioaustralasine

(+)-trans-Erioaustralasine

C22H25NO5 (383.1733)


   

Chlorolissoclimide

Chlorolissoclimide

C20H30ClNO4 (383.1863)


   

Heterophylloidine

Heterophylloidine

C23H29NO4 (383.2096)


   
   
   
   

N,N-Dimethyl-2-(1,2,3-trimethoxynaphtho(2,1-f)(1,3)benzodioxol-4-yl)ethanamine

N,N-Dimethyl-2-(1,2,3-trimethoxynaphtho(2,1-f)(1,3)benzodioxol-4-yl)ethanamine

C22H25NO5 (383.1733)


   

Dihydrozeatin O-glucoside

Dihydrozeatin O-glucoside

C16H25N5O6 (383.1805)


   

Epocarbazolin B

Epocarbazolin B

C23H29NO4 (383.2096)


   
   

Daphnilongeranin A

methyl (1S,2S,5S)-2,6-dimethyl-21-oxo-14-oxa-8-azahexacyclo[11.6.1.11,5.02,10.03,8.017,20]henicosa-13(20),17-diene-18-carboxylate

C23H29NO4 (383.2096)


   

Paxiphylline D

Paxiphylline D

C23H29NO4 (383.2096)


   

2-(2,3-Dimethoxyphenyl)-5,8-dimethoxy-3-propyl-4(1H)-quinolinone

2-(2,3-Dimethoxyphenyl)-5,8-dimethoxy-3-propyl-4(1H)-quinolinone

C22H25NO5 (383.1733)


   
   
   
   

1-[1-(3,4-Dichlorobenzamidomethyl)cyclohexyl]-4-methylpiperazine

1-[1-(3,4-Dichlorobenzamidomethyl)cyclohexyl]-4-methylpiperazine

C19H27Cl2N3O (383.1531)


   

SCHEMBL15444611

SCHEMBL15444611

C22H25NO5 (383.1733)


   

LPC 8:0

1-Octanoyl-sn-glycerol-3-phosphorylcholine

C16H34NO7P (383.2073)


   

O-methylandrocymbine

O-methylandrocymbine

C23H29NO4 (383.2096)


   

LEUCOGENENOL

LEUCOGENENOL

C18H25NO8 (383.158)


   

3-O-(2-Acetamido-2-deoxy-a-D-glucopyranosyl)-D-galactose

3-O-(2-Acetamido-2-deoxy-a-D-glucopyranosyl)-D-galactose

C14H25NO11 (383.1428)


   
   

3,4-dimethoxy-6,13-dimethyl-5,7,8,15-tetrahydro-6H-benzo[c][1,3]dioxolo[4,5:4,5]benzo[1,2-g]azecin-14-one

3,4-dimethoxy-6,13-dimethyl-5,7,8,15-tetrahydro-6H-benzo[c][1,3]dioxolo[4,5:4,5]benzo[1,2-g]azecin-14-one

C22H25NO5 (383.1733)


   

12,13,19-trihydroxy-15,20-epoxy-15,20-dihydro, (12S,15R,20R)senecionan-11,16-dione|15,20-Epoxy-15,20-dihydro-12,13,19-trihydroxy-11,16-senecionanedione|Adonifoline

12,13,19-trihydroxy-15,20-epoxy-15,20-dihydro, (12S,15R,20R)senecionan-11,16-dione|15,20-Epoxy-15,20-dihydro-12,13,19-trihydroxy-11,16-senecionanedione|Adonifoline

C18H25NO8 (383.158)


   

daphnicyclidin C

daphnicyclidin C

C22H25NO5 (383.1733)


   
   

(+/-)-raddeanamine

(+/-)-raddeanamine

C22H25NO5 (383.1733)


   

3-O-[2-(Acetamino)-2-deoxy-D-galactopyranosyl]-D-mannopyranose

3-O-[2-(Acetamino)-2-deoxy-D-galactopyranosyl]-D-mannopyranose

C14H25NO11 (383.1428)


   

scaevodimerine A

scaevodimerine A

C21H25N3O4 (383.1845)


   

6-[(Isopropyloxy)methyl]-6,7,12,13-tetrahydro-5H-indolo[2,3-a]pyrrolo[3,4-c]carbazol-5-one

6-[(Isopropyloxy)methyl]-6,7,12,13-tetrahydro-5H-indolo[2,3-a]pyrrolo[3,4-c]carbazol-5-one

C24H21N3O2 (383.1634)


   

2-Acetamido-2-deoxy-3-O-(|A-D-galactopyranosyl)-D-galactose

2-Acetamido-2-deoxy-3-O-(|A-D-galactopyranosyl)-D-galactose

C14H25NO11 (383.1428)


   
   

9H-Purin-6-amine, N-(3-methylbutyl)-2-(methylthio)-9-pentofuranosyl-

9H-Purin-6-amine, N-(3-methylbutyl)-2-(methylthio)-9-pentofuranosyl-

C16H25N5O4S (383.1627)


   

3,7-diacetyl-intermedine|3,7-Diacetylintermedine|3,7-Diacetyllycopsamine|Di-O-acetylindicin

3,7-diacetyl-intermedine|3,7-Diacetylintermedine|3,7-Diacetyllycopsamine|Di-O-acetylindicin

C19H29NO7 (383.1944)


   

(+/-)-Corycavidine

(+/-)-Corycavidine

C22H25NO5 (383.1733)


   

Adonifoline

Adonifoline

C18H25NO8 (383.158)


   

5,8-dimethoxy-2-(3,4-dimethoxyphenyl)-3-propyl-1h-quinolin-4-one

5,8-dimethoxy-2-(3,4-dimethoxyphenyl)-3-propyl-1h-quinolin-4-one

C22H25NO5 (383.1733)


   
   

(16S)-10-methoxyisositsirikine

(16S)-10-methoxyisositsirikine

C23H29NO4 (383.2096)


   

(7Xi,8S)-8,6,7-trimethoxy-2-methyl-6,8,3,4-tetrahydro-2H-spiro[indeno[4,5-d][1,3]dioxole-7,1-isoquinoline]|Fumaritrin

(7Xi,8S)-8,6,7-trimethoxy-2-methyl-6,8,3,4-tetrahydro-2H-spiro[indeno[4,5-d][1,3]dioxole-7,1-isoquinoline]|Fumaritrin

C22H25NO5 (383.1733)


   
   

Me glycoside,N,4-O-dibenzoyl-beta-L-Pyranose-3-Amino-2,3,6-trideoxy-3-C-methyl-xylo-hexose

Me glycoside,N,4-O-dibenzoyl-beta-L-Pyranose-3-Amino-2,3,6-trideoxy-3-C-methyl-xylo-hexose

C22H25NO5 (383.1733)


   

Antibiotic LL-AM 31gammar

Antibiotic LL-AM 31gammar

C14H29N3O9 (383.1904)


   

daphhimalenine B

daphhimalenine B

C23H29NO4 (383.2096)


   

monascopyridine B

monascopyridine B

C23H29NO4 (383.2096)


   
   

N-[2-(7-Hydroxy-3,4,6-trimethoxyphenanthren-1-yl)ethyl]-N-methylacetamide

N-[2-(7-Hydroxy-3,4,6-trimethoxyphenanthren-1-yl)ethyl]-N-methylacetamide

C22H25NO5 (383.1733)


   

O4-(2-acetylamino-2-deoxy-alpha-D-galactopyranosyl)-D-galactose|O4-(2-Acetylamino-2-desoxy-alpha-D-galactopyranosyl)-D-galactose

O4-(2-acetylamino-2-deoxy-alpha-D-galactopyranosyl)-D-galactose|O4-(2-Acetylamino-2-desoxy-alpha-D-galactopyranosyl)-D-galactose

C14H25NO11 (383.1428)


   
   

Me glycoside,N,4-dibenzoyl-alpha-L-Pyranose-3-Amino-2,3,6-trideoxy-3-C-methyl-xylo-hexose

Me glycoside,N,4-dibenzoyl-alpha-L-Pyranose-3-Amino-2,3,6-trideoxy-3-C-methyl-xylo-hexose

C22H25NO5 (383.1733)


   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   

Spiramide

8-(3-(4-Fluorophenoxy) propyl)-1-phenyl-1,3,8-triazaspiro(4, 5)decan-4-one

C22H26FN3O2 (383.2009)


Spiramide is an azaspiro compound that consists of 1,3,8-triazaspiro[4.5]decan-4-one having a phenyl group attached to N-1 and a 3-(4-fluorophenoxy)propyl attached to N-8. Selective 5-HT antagonist, which binds to 5-HT2 sites as potently as spiperone but has lower affinity for 5-HT2C receptors. Also a high affinity D2 receptor antagonist (Ki = 3 nM). Lacks the disruptive effect of spiperone on animal behaviour. It has a role as a dopaminergic antagonist and a serotonergic antagonist. It is an azaspiro compound, an organofluorine compound, an aromatic ether, a tertiary amino compound and a member of piperidines. Spiramide is a natural product found in Spiraea japonica with data available. C78272 - Agent Affecting Nervous System > C29710 - Antipsychotic Agent Spiramide (AMI-193) is a potent and selective antagonist of 5-HT2 and dopamine D2 receptor, with Kis of 2 nM and 3 nM, respectively. Spiramide has >2000-fold selectivity for 5-HT2 versus 5-HT1C (Ki=4300 nM) receptors. Spiramide exhibits antipsychotic activity[1][2][3]. Spiramide (AMI-193) is a potent and selective antagonist of 5-HT2 and dopamine D2 receptor, with Kis of 2 nM and 3 nM, respectively. Spiramide has >2000-fold selectivity for 5-HT2 versus 5-HT1C (Ki=4300 nM) receptors. Spiramide exhibits antipsychotic activity[1][2][3]. Spiramide (AMI-193) is a potent and selective antagonist of 5-HT2 and dopamine D2 receptor, with Kis of 2 nM and 3 nM, respectively. Spiramide has >2000-fold selectivity for 5-HT2 versus 5-HT1C (Ki=4300 nM) receptors. Spiramide exhibits antipsychotic activity[1][2][3].

   

Dehydrocorydaline (hydroxyl)

Dehydrocorydaline (hydroxyl)

C22H25NO5 (383.1733)


   

dihydrozeatin-9-b-D-glucoside

dihydrozeatin-9-b-D-glucoside

C16H25N5O6 (383.1805)


   

prazosin

prazosin

C19H21N5O4 (383.1593)


C - Cardiovascular system > C02 - Antihypertensives > C02C - Antiadrenergic agents, peripherally acting > C02CA - Alpha-adrenoreceptor antagonists C78272 - Agent Affecting Nervous System > C29747 - Adrenergic Agent > C72900 - Adrenergic Antagonist D018377 - Neurotransmitter Agents > D018663 - Adrenergic Agents > D018674 - Adrenergic Antagonists C78274 - Agent Affecting Cardiovascular System > C270 - Antihypertensive Agent COVID info from clinicaltrial, clinicaltrials, clinical trial, clinical trials D002317 - Cardiovascular Agents > D000959 - Antihypertensive Agents Corona-virus Coronavirus SARS-CoV-2 COVID-19 SARS-CoV COVID19 SARS2 SARS relative retention time with respect to 9-anthracene Carboxylic Acid is 0.767 relative retention time with respect to 9-anthracene Carboxylic Acid is 0.759 relative retention time with respect to 9-anthracene Carboxylic Acid is 0.760 Prazosin is an alpha-adrenergic blocker and is a sympatholytic drug used to treat high blood pressure and anxiety, PTSD, and panic disorder. Target: Adrenergic Receptor Prazosin, is a sympatholytic drug used to treat high blood pressure and anxiety, PTSD, andpanic disorder. It is an alpha-adrenergic blocker that is specific for the alpha-1 receptors. These receptors are found on vascular smooth muscle, where they are responsible for the vasoconstrictive action of norepinephrine. They are also found throughout the central nervous system. As of 2013, prazosin is off-patent in the US, and the FDA has approved at least one generic manufacturer.In addition to its alpha-blocking activity, prazosin is an antagonist of the MT3 receptor (which is not present in humans), with selectivity for this receptor over the MT1 and MT2 receptors. Prazosin is orally active and has a minimal effect on cardiac function due to its alpha-1 receptor selectivity. However, when prazosin is initially started, heart rate and contractility go up in order to maintain the pre-treatment blood pressures because the body has reached homeostasis at its abnormally high blood pressure. The blood pressure lowering effect becomes apparent when prazosin is taken for longer periods of time. The heart rate and contractility go back down over time and blood pressure decreases.

   

(6aS)-1,2,9,10-tetramethoxy-6-methyl-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinoline-3-carbaldehyde

(6aS)-1,2,9,10-tetramethoxy-6-methyl-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinoline-3-carbaldehyde

C22H25NO5 (383.1733)


relative retention time with respect to 9-anthracene Carboxylic Acid is 0.778 relative retention time with respect to 9-anthracene Carboxylic Acid is 0.773

   

6,7-Dimethoxy-1-[2-(2,3,4-trimethoxy-phenyl)-vinyl]-3,4-dihydro-isoquinoline

"NCGC00160170-01!6,7-Dimethoxy-1-[2-(2,3,4-trimethoxy-phenyl)-vinyl]-3,4-dihydro-isoquinoline"

C22H25NO5 (383.1733)


   

Peniprequinolone_120176

Peniprequinolone_120176

C22H25NO5 (383.1733)


   

C22H25NO5_(3R,4R)-4,5-Dihydroxy-3-methoxy-4-(4-methoxyphenyl)-6-(3-methyl-2-buten-1-yl)-3,4-dihydro-2(1H)-quinolinone

NCGC00169912-03_C22H25NO5_(3R,4R)-4,5-Dihydroxy-3-methoxy-4-(4-methoxyphenyl)-6-(3-methyl-2-buten-1-yl)-3,4-dihydro-2(1H)-quinolinone

C22H25NO5 (383.1733)


   

N-acetyllactosamine

N-Acetyl-D-lactosamine

C14H25NO11 (383.1428)


A beta-D-galactopyranosyl-(1->4)-N-acetyl-D-glucosamine having beta-configuration at the reducing end anomeric centre. N-Acetyllactosamine (LacNAc), a nitrogen-containing disaccharide, is an important component of various oligosaccharides such as glycoproteins and sialyl Lewis X. N-Acetyllactosamine can be used as the starting material for the synthesis of various oligosaccharides. N-Acetyllactosamine has prebiotic effects[1][2].

   

quetiapine

quetiapine

C21H25N3O2S (383.1667)


N - Nervous system > N05 - Psycholeptics > N05A - Antipsychotics > N05AH - Diazepines, oxazepines, thiazepines and oxepines D002492 - Central Nervous System Depressants > D014149 - Tranquilizing Agents > D014150 - Antipsychotic Agents D002491 - Central Nervous System Agents > D011619 - Psychotropic Drugs > D000928 - Antidepressive Agents D002491 - Central Nervous System Agents > D011619 - Psychotropic Drugs > D014149 - Tranquilizing Agents D002491 - Central Nervous System Agents > D002492 - Central Nervous System Depressants COVID info from clinicaltrial, clinicaltrials, clinical trial, clinical trials C78272 - Agent Affecting Nervous System > C66885 - Serotonin Antagonist C78272 - Agent Affecting Nervous System > C29710 - Antipsychotic Agent Corona-virus Coronavirus SARS-CoV-2 COVID-19 SARS-CoV COVID19 SARS2 SARS Quetiapine (ICI204636) is a 5-HT receptors agonist with a pEC50 of 4.77 for human 5-HT1A receptor. Quetiapine is a dopamine receptor antagonist with a pIC50 of 6.33 for human D2 receptor. Quetiapine has moderate to high affinity for the human D2, HT1A, 5-HT2A, 5-HT2C receptor with pKis of 7.25, 5.74, 7.54, 5.55. Antidepressant and anxiolytic effects[1].

   

peniprequinolone

peniprequinolone

C22H25NO5 (383.1733)


   

VERALIPRIDE

VERALIPRIDE

C17H25N3O5S (383.1515)


D002492 - Central Nervous System Depressants > D014149 - Tranquilizing Agents > D014150 - Antipsychotic Agents D002491 - Central Nervous System Agents > D011619 - Psychotropic Drugs > D014149 - Tranquilizing Agents D002491 - Central Nervous System Agents > D002492 - Central Nervous System Depressants N - Nervous system > N05 - Psycholeptics > N05A - Antipsychotics > N05AL - Benzamides C78272 - Agent Affecting Nervous System > C66883 - Dopamine Antagonist Veralipride is a D2 receptor antagonist. It is an alternative antidopaminergic treatment for menopausal symptoms.

   

Gly Gly His Asn

(2S)-2-[(2S)-2-[2-(2-aminoacetamido)acetamido]-3-(1H-imidazol-4-yl)propanamido]-3-carbamoylpropanoic acid

C14H21N7O6 (383.1553)


   

Gly Gly Asn His

(2S)-2-[(2S)-2-[2-(2-aminoacetamido)acetamido]-3-carbamoylpropanamido]-3-(1H-imidazol-4-yl)propanoic acid

C14H21N7O6 (383.1553)


   

Gly His Gly Asn

(2S)-2-{2-[(2S)-2-(2-aminoacetamido)-3-(1H-imidazol-4-yl)propanamido]acetamido}-3-carbamoylpropanoic acid

C14H21N7O6 (383.1553)


   

Gly His Asn Gly

2-[(2S)-2-[(2S)-2-(2-aminoacetamido)-3-(1H-imidazol-4-yl)propanamido]-3-carbamoylpropanamido]acetic acid

C14H21N7O6 (383.1553)


   

Gly Asn Gly His

(2S)-2-{2-[(2S)-2-(2-aminoacetamido)-3-carbamoylpropanamido]acetamido}-3-(1H-imidazol-4-yl)propanoic acid

C14H21N7O6 (383.1553)


   

Gly Asn His Gly

2-[(2S)-2-[(2S)-2-(2-aminoacetamido)-3-carbamoylpropanamido]-3-(1H-imidazol-4-yl)propanamido]acetic acid

C14H21N7O6 (383.1553)


   

Gly Asn Pro Pro

(2S)-1-{[(2S)-1-[(2S)-2-(2-aminoacetamido)-3-carbamoylpropanoyl]pyrrolidin-2-yl]carbonyl}pyrrolidine-2-carboxylic acid

C16H25N5O6 (383.1805)


   

Gly Pro Asn Pro

(2S)-1-[(2S)-2-{[(2S)-1-(2-aminoacetyl)pyrrolidin-2-yl]formamido}-3-carbamoylpropanoyl]pyrrolidine-2-carboxylic acid

C16H25N5O6 (383.1805)


   

Gly Pro Pro Asn

(2S)-2-{[(2S)-1-{[(2S)-1-(2-aminoacetyl)pyrrolidin-2-yl]carbonyl}pyrrolidin-2-yl]formamido}-3-carbamoylpropanoic acid

C16H25N5O6 (383.1805)


   

His Gly Gly Asn

(2S)-2-(2-{2-[(2S)-2-amino-3-(1H-imidazol-4-yl)propanamido]acetamido}acetamido)-3-carbamoylpropanoic acid

C14H21N7O6 (383.1553)


   

His Gly Asn Gly

2-[(2S)-2-{2-[(2S)-2-amino-3-(1H-imidazol-4-yl)propanamido]acetamido}-3-carbamoylpropanamido]acetic acid

C14H21N7O6 (383.1553)


   

His Asn Gly Gly

2-{2-[(2S)-2-[(2S)-2-amino-3-(1H-imidazol-4-yl)propanamido]-3-carbamoylpropanamido]acetamido}acetic acid

C14H21N7O6 (383.1553)


   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   

Asn Gly Gly His

(2S)-2-(2-{2-[(2S)-2-amino-3-carbamoylpropanamido]acetamido}acetamido)-3-(1H-imidazol-4-yl)propanoic acid

C14H21N7O6 (383.1553)


   

Asn Gly His Gly

2-[(2S)-2-{2-[(2S)-2-amino-3-carbamoylpropanamido]acetamido}-3-(1H-imidazol-4-yl)propanamido]acetic acid

C14H21N7O6 (383.1553)


   

Asn Gly Pro Pro

(2S)-1-{[(2S)-1-{2-[(2S)-2-amino-3-carbamoylpropanamido]acetyl}pyrrolidin-2-yl]carbonyl}pyrrolidine-2-carboxylic acid

C16H25N5O6 (383.1805)


   

Asn His Gly Gly

2-{2-[(2S)-2-[(2S)-2-amino-3-carbamoylpropanamido]-3-(1H-imidazol-4-yl)propanamido]acetamido}acetic acid

C14H21N7O6 (383.1553)


   
   

Asn Pro Gly Pro

(2S)-1-(2-{[(2S)-1-[(2S)-2-amino-3-carbamoylpropanoyl]pyrrolidin-2-yl]formamido}acetyl)pyrrolidine-2-carboxylic acid

C16H25N5O6 (383.1805)


   

Asn Pro Pro Gly

2-{[(2S)-1-{[(2S)-1-[(2S)-2-amino-3-carbamoylpropanoyl]pyrrolidin-2-yl]carbonyl}pyrrolidin-2-yl]formamido}acetic acid

C16H25N5O6 (383.1805)


   
   
   
   

Pro Gly Asn Pro

(2S)-1-[(2S)-3-carbamoyl-2-{2-[(2S)-pyrrolidin-2-ylformamido]acetamido}propanoyl]pyrrolidine-2-carboxylic acid

C16H25N5O6 (383.1805)


   

Pro Gly Pro Asn

(2S)-3-carbamoyl-2-{[(2S)-1-{2-[(2S)-pyrrolidin-2-ylformamido]acetyl}pyrrolidin-2-yl]formamido}propanoic acid

C16H25N5O6 (383.1805)


   

Pro Asn Gly Pro

(2S)-1-{2-[(2S)-3-carbamoyl-2-[(2S)-pyrrolidin-2-ylformamido]propanamido]acetyl}pyrrolidine-2-carboxylic acid

C16H25N5O6 (383.1805)


   

Pro Asn Pro Gly

2-{[(2S)-1-[(2S)-3-carbamoyl-2-[(2S)-pyrrolidin-2-ylformamido]propanoyl]pyrrolidin-2-yl]formamido}acetic acid

C16H25N5O6 (383.1805)


   

Pro Pro Gly Asn

(2S)-3-carbamoyl-2-(2-{[(2S)-1-{[(2S)-pyrrolidin-2-yl]carbonyl}pyrrolidin-2-yl]formamido}acetamido)propanoic acid

C16H25N5O6 (383.1805)


   

Pro Pro Asn Gly

2-[(2S)-3-carbamoyl-2-{[(2S)-1-{[(2S)-pyrrolidin-2-yl]carbonyl}pyrrolidin-2-yl]formamido}propanamido]acetic acid

C16H25N5O6 (383.1805)


   
   
   
   
   
   
   
   
   
   
   
   

Platelet-activating factor

3,5,9-Trioxa-4-phosphapentadecan-1-aminium, 7-(acetyloxy)-4-hydroxy-N,N,N-trimethyl-, inner salt, 4-oxide, (1)-

C16H34NO7P (383.2073)


   

1-Octanoyllysolecithin

3,5,9-Trioxa-4-phosphaheptadecan-1-aminium, 4,7-dihydroxy-N,N,N-trimethyl-10-oxo-, inner salt, 4-oxide, (R)-

C16H34NO7P (383.2073)


   

PC(8:0/0:0)[U]

3,5,9-Trioxa-4-phosphaheptadecan-1-aminium, 4,7-dihydroxy-N,N,N-trimethyl-10-oxo-, inner salt, 4-oxide

C16H34NO7P (383.2073)


   

PC(0:0/8:0)[U]

3,5,8-Trioxa-4-phosphahexadecan-1-aminium, 4-hydroxy-7-(hydroxymethyl)-N,N,N-trimethyl-9-oxo-, inner salt, 4-oxide

C16H34NO7P (383.2073)


   

Not Available

Beta-1,4-mannose-N-acetylglucosamine

C14H25NO11 (383.1428)


   

Dihydrozeatin-7-N-dihydrozeatin

Dihydrozeatin-7-N-dihydrozeatin

C16H25N5O6 (383.1805)


   

Dihydrozeatin-9-N-glucoside

Dihydrozeatin-9-N-glucoside

C16H25N5O6 (383.1805)


   

Dihydrozeatin-O-glucoside

Dihydrozeatin-O-glucoside

C16H25N5O6 (383.1805)


   

Niazimin A

6-(4-{[(ethoxycarbonyl)amino]methyl}phenoxy)-4,5-dihydroxy-2-methyloxan-3-yl acetate

C18H25NO8 (383.158)


   

Deflazacort intermediate

Deflazacort intermediate

C23H29NO4 (383.2096)


   

N-Boc-4-[2-(4-Toluenesulfonyloxy)ethyl]piperidine

N-Boc-4-[2-(4-Toluenesulfonyloxy)ethyl]piperidine

C19H29NO5S (383.1766)


   

PD 117519

PD 117519

C19H21N5O4 (383.1593)


PD 117519 (CI947) is an A2A adenosine agonist which has shown oral antihypertensive activity in pharmacological animal models[1][2]. PD 117519 (CI947) is an A2A adenosine agonist which has shown oral antihypertensive activity in pharmacological animal models[1][2].

   

1-(diphenylmethyl)azetidin-3-yl 2-carbamimidoylacetate acetate

1-(diphenylmethyl)azetidin-3-yl 2-carbamimidoylacetate acetate

C21H25N3O4 (383.1845)


   

tert-Butyl (3R,4R)-4-(4-benzyloxyphenyl)-3-hydroxypiperidine-1-carboxylate

tert-Butyl (3R,4R)-4-(4-benzyloxyphenyl)-3-hydroxypiperidine-1-carboxylate

C23H29NO4 (383.2096)


   

Trifenagrel

Trifenagrel

C25H25N3O (383.1998)


C78275 - Agent Affecting Blood or Body Fluid > C1327 - Antiplatelet Agent

   

CA 074 TFA

[L-3-trans-(Propylcarbamoyl)oxirane-2-carbonyl]-L-isoleucyl-L-proline

C18H29N3O6 (383.2056)


D004791 - Enzyme Inhibitors > D011480 - Protease Inhibitors > D015853 - Cysteine Proteinase Inhibitors D002491 - Central Nervous System Agents > D018696 - Neuroprotective Agents D020011 - Protective Agents

   

2-Acetamido-2-deoxy-6-O-(b-D-galactopyranosyl)-D-galactopyranose

2-Acetamido-2-deoxy-6-O-(b-D-galactopyranosyl)-D-galactopyranose

C14H25NO11 (383.1428)


   

3-O-(2-Acetamido-2-deoxy-b-D-glucopyranosyl)-D-mannopyranose

3-O-[2-Acetamido-2-deoxy-beta-D-glucopyranosyl]-D-mannopyranose

C14H25NO11 (383.1428)


   

beta-D-Galp-(1->6)-D-GlcNAcp

2-Acetamido-2-deoxy-6-O-(b-D-galactopyranosyl)-D-glucopyranose

C14H25NO11 (383.1428)


An amino disaccharide consisting of N-acetyl-D-glucosamine having a beta-D-galactosyl residue attached at the 6-position.

   
   

nalpha-fmoc-l-serine tert-butyl ester

nalpha-fmoc-l-serine tert-butyl ester

C22H25NO5 (383.1733)


   

1-Piperidinecarboxylic acid, 3-hydroxy-4-[4-(phenylmethoxy)phenyl]-, 1,1-dimethylethyl ester, trans

1-Piperidinecarboxylic acid, 3-hydroxy-4-[4-(phenylmethoxy)phenyl]-, 1,1-dimethylethyl ester, trans

C23H29NO4 (383.2096)


   

Anagliptin

Anagliptin

C19H25N7O2 (383.207)


C78276 - Agent Affecting Digestive System or Metabolism > C29711 - Anti-diabetic Agent > C98086 - Dipeptidyl Peptidase-4 Inhibitor D007004 - Hypoglycemic Agents > D054873 - Dipeptidyl-Peptidase IV Inhibitors D004791 - Enzyme Inhibitors > D011480 - Protease Inhibitors C471 - Enzyme Inhibitor > C783 - Protease Inhibitor

   

(2R,4S)-5-(Biphenyl-4-yl)-4-[(tert-butoxycarbonyl)amino]-2-methylpentanoic acid

(2R,4S)-5-(Biphenyl-4-yl)-4-[(tert-butoxycarbonyl)amino]-2-methylpentanoic acid

C23H29NO4 (383.2096)


   

Gal-alpha1,3-GalNAc

2-ACETAMIDO-2-DEOXY-3-O-(ALPHA-D-GALACTOPYRANOSYL)-D-GALACTOSE

C14H25NO11 (383.1428)


   

3-Methyl-2-(tributylstannyl)pyridine

3-Methyl-2-(tributylstannyl)pyridine

C18H33NSn (383.1635)


   

FMOC-(2S,3S)-3-AMINO-2-HYDROXY-5-METHYLHEXANOIC ACID

FMOC-(2S,3S)-3-AMINO-2-HYDROXY-5-METHYLHEXANOIC ACID

C22H25NO5 (383.1733)


   

5-Methyl-2-(tributylstannyl)pyridine

5-Methyl-2-(tributylstannyl)pyridine

C18H33NSn (383.1635)


   

1-(Diphenylmethyl)-3-azetidinyl 3,3-diaminoacrylate acetate (1:1)

1-(Diphenylmethyl)-3-azetidinyl 3,3-diaminoacrylate acetate (1:1)

C21H25N3O4 (383.1845)


   

4-Methyl-2-(tributylstannyl)pyridine

4-Methyl-2-(tributylstannyl)pyridine

C18H33NSn (383.1635)


   

2-Methyl-6-(tributylstannyl)pyridine

2-Methyl-6-(tributylstannyl)pyridine

C18H33NSn (383.1635)


   

Fmoc-Ser(tBu)-OH

Fmoc-Ser(tBu)-OH

C22H25NO5 (383.1733)


   

N-FMOC-O-tert-butyl-L-Threoninol

N-FMOC-O-tert-butyl-L-Threoninol

C23H29NO4 (383.2096)


   

Fmoc-Thr(tBu)-ol

Fmoc-Thr(tBu)-ol

C23H29NO4 (383.2096)


   

N-(1-(2-(1H-INDOL-3-YL)ETHYL)PIPERIDIN-4-YL)BENZAMIDE HYDROCHLORIDE

N-(1-(2-(1H-INDOL-3-YL)ETHYL)PIPERIDIN-4-YL)BENZAMIDE HYDROCHLORIDE

C22H26ClN3O (383.1764)


   

(2S,4S)-5-([1,1-biphenyl]-4-yl)-4-((tert-butoxycarbonyl)amino)-2-methylpentanoic acid

(2S,4S)-5-([1,1-biphenyl]-4-yl)-4-((tert-butoxycarbonyl)amino)-2-methylpentanoic acid

C23H29NO4 (383.2096)


   

(2S,4R)-5-([1,1-biphenyl]-4-yl)-4-((tert-butoxycarbonyl)amino)-2-methylpentanoic acid

(2S,4R)-5-([1,1-biphenyl]-4-yl)-4-((tert-butoxycarbonyl)amino)-2-methylpentanoic acid

C23H29NO4 (383.2096)


   

2-(chloromethyl)oxirane; oxirane

2-(chloromethyl)oxirane; oxirane

C19H25N7O2 (383.207)


   

9-(3-Methylphenyl)-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-9H-carbazole

9-(3-Methylphenyl)-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-9H-carbazole

C25H26BNO2 (383.2056)


   

3-O-[2-(Acetylamino)-2-deoxy-D-galactopyranosyl]-D-mannopyranose

3-O-[2-(Acetylamino)-2-deoxy-D-galactopyranosyl]-D-mannopyranose

C14H25NO11 (383.1428)


   

(3,3,4,4,4-D5)-(E/Z)-1-[4-(2-CHLOROETHOXY)PHENYL]-1-[4-HYDROXYPHENYL]-2-PHENYL-1-BUTENE

(3,3,4,4,4-D5)-(E/Z)-1-[4-(2-CHLOROETHOXY)PHENYL]-1-[4-HYDROXYPHENYL]-2-PHENYL-1-BUTENE

C24H18ClD5O2 (383.17)


   

3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-9-(p-tolyl)-9H-carbazole

3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-9-(p-tolyl)-9H-carbazole

C25H26BNO2 (383.2056)


   

4-(trans-4-Propylcyclohexyl)benzoic acid 4-cyano-3,5-difluorophenyl ester

4-(trans-4-Propylcyclohexyl)benzoic acid 4-cyano-3,5-difluorophenyl ester

C23H23F2NO2 (383.1697)


   

4-Cyanobiphenyl-4-hexylbenzoate

4-Cyanobiphenyl-4-hexylbenzoate

C26H25NO2 (383.1885)


   

Fmoc-D-Ser(tBu)-OH

Fmoc-D-Ser(tBu)-OH

C22H25NO5 (383.1733)


   

Technetium tc 99m exametazime

Technetium tc 99m exametazime

C13H25N4O3Tc (383.1927)


D019995 - Laboratory Chemicals > D007202 - Indicators and Reagents > D019275 - Radiopharmaceuticals C1446 - Radiopharmaceutical Compound > C2124 - Radioconjugate

   

3-((2-Carboxybiphenyl-4-yl)methyl)-2-cyclopropyl-7-methyl-3H-imidazo(4,5-b)pyridine

3-((2-Carboxybiphenyl-4-yl)methyl)-2-cyclopropyl-7-methyl-3H-imidazo(4,5-b)pyridine

C24H21N3O2 (383.1634)


D057911 - Angiotensin Receptor Antagonists > D047228 - Angiotensin II Type 1 Receptor Blockers

   

Methyl (1-(4-fluorobenzyl)-1H-indazole-3-carbonyl)-DL-valinate

Methyl (1-(4-fluorobenzyl)-1H-indazole-3-carbonyl)-DL-valinate

C21H22FN3O3 (383.1645)


   

2-Acetamido-2-deoxy-3-O-hexopyranosylhexose

2-Acetamido-2-deoxy-3-O-hexopyranosylhexose

C14H25NO11 (383.1428)


   

N-((1-(2-(tert-Butylamino)-2-oxoethyl)piperidin-4-yl)methyl)-3-chloro-5-fluorobenzamide

N-((1-(2-(tert-Butylamino)-2-oxoethyl)piperidin-4-yl)methyl)-3-chloro-5-fluorobenzamide

C19H27ClFN3O2 (383.1776)


C78274 - Agent Affecting Cardiovascular System > C270 - Antihypertensive Agent > C333 - Calcium Channel Blocker D002317 - Cardiovascular Agents > D002121 - Calcium Channel Blockers D000077264 - Calcium-Regulating Hormones and Agents D049990 - Membrane Transport Modulators C93038 - Cation Channel Blocker

   

Panicutine

Panicutine

C23H29NO4 (383.2096)


A natural product found in Aconitum paniculatum and Delphinium denudatum.

   

Lacto-N-biose II

Lacto-N-biose II

C14H25NO11 (383.1428)


   

3-(2-Hydroxy-4,6-dimethoxyphenyl)-1-(3-methyl-1-piperidinyl)-3-phenyl-1-propanone

3-(2-Hydroxy-4,6-dimethoxyphenyl)-1-(3-methyl-1-piperidinyl)-3-phenyl-1-propanone

C23H29NO4 (383.2096)


   

2-Acetamido-2-deoxy-6-O-beta galactopyranosylgalactopyranose

2-Acetamido-2-deoxy-6-O-beta galactopyranosylgalactopyranose

C14H25NO11 (383.1428)


   

2-Acetamido-2-deoxy-4-O-(B-D-galactopyranosyl)-D-galactopyranose

2-Acetamido-2-deoxy-4-O-(B-D-galactopyranosyl)-D-galactopyranose

C14H25NO11 (383.1428)


   

N-[(2R,3R,4R,5S,6R)-4,5-Dihydroxy-6-(hydroxymethyl)-2-[(2R,3R,4R,5R)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]acetamide

N-[(2R,3R,4R,5S,6R)-4,5-Dihydroxy-6-(hydroxymethyl)-2-[(2R,3R,4R,5R)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]acetamide

C14H25NO11 (383.1428)


   
   

L-Alanyl-L-phenylalanyl-L-phenylalanine

L-Alanyl-L-phenylalanyl-L-phenylalanine

C21H25N3O4 (383.1845)


   

beta-D-GalNAc-(1->3)-D-Gal

beta-D-GalNAc-(1->3)-D-Gal

C14H25NO11 (383.1428)


A glycosylgalactose derivative consisting of D-galactose having a beta-D-N-acetylgalactosaminyl residue attached at the 3-position.

   

4-O-(2-acetamido-2-deoxy-beta-D-galactopyranosyl)-D-galactopyranose

4-O-(2-acetamido-2-deoxy-beta-D-galactopyranosyl)-D-galactopyranose

C14H25NO11 (383.1428)


   

N-[(2R,3R,4R,5S,6R)-4,5-Dihydroxy-6-(hydroxymethyl)-2-[[(2R,3R,4S,5R)-3,4,5,6-tetrahydroxyoxan-2-yl]methoxy]oxan-3-yl]acetamide

N-[(2R,3R,4R,5S,6R)-4,5-Dihydroxy-6-(hydroxymethyl)-2-[[(2R,3R,4S,5R)-3,4,5,6-tetrahydroxyoxan-2-yl]methoxy]oxan-3-yl]acetamide

C14H25NO11 (383.1428)


   

2-Acetamido-2-deoxy-4-O-beta-D-galactopyranosyl-D-mannopyranose

2-Acetamido-2-deoxy-4-O-beta-D-galactopyranosyl-D-mannopyranose

C14H25NO11 (383.1428)


   

2-(Acetylamino)-2-deoxy-4-O-beta-D-galactopyranosyl-alpha-D-glucopyranose

2-(Acetylamino)-2-deoxy-4-O-beta-D-galactopyranosyl-alpha-D-glucopyranose

C14H25NO11 (383.1428)


   

N-({(2S)-1-[(3R)-3-Amino-4-(2-fluorophenyl)butanoyl]pyrrolidin-2-YL}methyl)benzamide

N-({(2S)-1-[(3R)-3-Amino-4-(2-fluorophenyl)butanoyl]pyrrolidin-2-YL}methyl)benzamide

C22H26FN3O2 (383.2009)


   

4-({(2R,5S)-2,5-Dimethyl-4-[(2R)-3,3,3-trifluoro-2-hydroxy-2-methylpropanoyl]piperazin-1-YL}carbonyl)benzonitrile

4-({(2R,5S)-2,5-Dimethyl-4-[(2R)-3,3,3-trifluoro-2-hydroxy-2-methylpropanoyl]piperazin-1-YL}carbonyl)benzonitrile

C18H20F3N3O3 (383.1457)


   

N-(4-Aminobutanoyl)-S-(4-methoxybenzyl)-L-cysteinylglycine

N-(4-Aminobutanoyl)-S-(4-methoxybenzyl)-L-cysteinylglycine

C17H25N3O5S (383.1515)


   

N-[2-(1-Maleimidyl)ethyl]-7-diethylaminocoumarin-3-carboxamide

N-[2-(1-Maleimidyl)ethyl]-7-diethylaminocoumarin-3-carboxamide

C20H21N3O5 (383.1481)


   

(1s,5s,7r)-N~7~-(Biphenyl-4-Ylmethyl)-N~3~-Hydroxy-6,8-Dioxa-3-Azabicyclo[3.2.1]octane-3,7-Dicarboxamide

(1s,5s,7r)-N~7~-(Biphenyl-4-Ylmethyl)-N~3~-Hydroxy-6,8-Dioxa-3-Azabicyclo[3.2.1]octane-3,7-Dicarboxamide

C20H21N3O5 (383.1481)


   

(2s)-1-{[5-(1h-Indazol-5-Yl)pyridin-3-Yl]oxy}-3-[(7as)-7ah-Indol-3-Yl]propan-2-Amine

(2s)-1-{[5-(1h-Indazol-5-Yl)pyridin-3-Yl]oxy}-3-[(7as)-7ah-Indol-3-Yl]propan-2-Amine

C23H21N5O (383.1746)


   

Losmapimod

Losmapimod

C22H26FN3O2 (383.2009)


C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C2149 - Mitogen-Activated Protein Kinase Inhibitor C471 - Enzyme Inhibitor > C1404 - Protein Kinase Inhibitor > C61074 - Serine/Threonine Kinase Inhibitor COVID info from clinicaltrial, clinicaltrials, clinical trial, clinical trials Corona-virus Coronavirus SARS-CoV-2 COVID-19 SARS-CoV COVID19 SARS2 SARS

   

1-Octanoyl-2-hydroxy-sn-glycero-3-phosphocholine

1-Octanoyl-2-hydroxy-sn-glycero-3-phosphocholine

C16H34NO7P (383.2073)


   

N-Acetyl-D-lactosamine

N-Acetyl-D-lactosamine

C14H25NO11 (383.1428)


N-Acetyllactosamine (LacNAc), a nitrogen-containing disaccharide, is an important component of various oligosaccharides such as glycoproteins and sialyl Lewis X. N-Acetyllactosamine can be used as the starting material for the synthesis of various oligosaccharides. N-Acetyllactosamine has prebiotic effects[1][2].

   

dihydrozeatin-7-N-glucose

dihydrozeatin-7-N-glucose

C16H25N5O6 (383.1805)


   
   

beta-D-Galp-(1->3)-beta-D-GalpNAc

beta-D-Galp-(1->3)-beta-D-GalpNAc

C14H25NO11 (383.1428)


A beta-D-Gal-(1->3)-D-GalNAc having beta-configuration at the reducing end anomeric centre.

   

beta-D-glucosaminyl-(1->4)-N-acetyl-D-glucosamine

beta-D-glucosaminyl-(1->4)-N-acetyl-D-glucosamine

C14H27N2O10+ (383.1666)


   

(3R)-1,2-didehydro-3-hydroxy-16-methoxy-2,3-dihydrotabersonine

(3R)-1,2-didehydro-3-hydroxy-16-methoxy-2,3-dihydrotabersonine

C22H27N2O4+ (383.1971)


   

(2R,3S,4S,5R,6S)-2-(hydroxymethyl)-6-[(2S)-2-methyl-4-(7H-purin-6-ylamino)butoxy]oxane-3,4,5-triol

(2R,3S,4S,5R,6S)-2-(hydroxymethyl)-6-[(2S)-2-methyl-4-(7H-purin-6-ylamino)butoxy]oxane-3,4,5-triol

C16H25N5O6 (383.1805)


   

N-acetyl-beta-D-glucosaminyl-(1->4)-D-glucosaminium(1+)

N-acetyl-beta-D-glucosaminyl-(1->4)-D-glucosaminium(1+)

C14H27N2O10+ (383.1666)


   

(2R,3S,4S,5R,6S)-2-(hydroxymethyl)-6-[6-[[(3S)-4-hydroxy-3-methylbutyl]amino]purin-9-yl]oxane-3,4,5-triol

(2R,3S,4S,5R,6S)-2-(hydroxymethyl)-6-[6-[[(3S)-4-hydroxy-3-methylbutyl]amino]purin-9-yl]oxane-3,4,5-triol

C16H25N5O6 (383.1805)


   

(4R,5S,6S)-3-[(3S,5S)-5-(dimethylcarbamoyl)pyrrolidin-1-ium-3-yl]sulfanyl-6-[(1R)-1-hydroxyethyl]-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylate

(4R,5S,6S)-3-[(3S,5S)-5-(dimethylcarbamoyl)pyrrolidin-1-ium-3-yl]sulfanyl-6-[(1R)-1-hydroxyethyl]-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylate

C17H25N3O5S (383.1515)


   

7-(Methylthio)heptyl-desulfoglucosinolate

7-(Methylthio)heptyl-desulfoglucosinolate

C15H29NO6S2 (383.1436)


   

3-Epoxy-16-methoxy-2,3-dihydrotabersonine

3-Epoxy-16-methoxy-2,3-dihydrotabersonine

C22H27N2O4+ (383.1971)


   

(2R,3S,4S,5R,6R)-2-(hydroxymethyl)-6-[(2S)-2-methyl-4-(7H-purin-6-ylamino)butoxy]oxane-3,4,5-triol

(2R,3S,4S,5R,6R)-2-(hydroxymethyl)-6-[(2S)-2-methyl-4-(7H-purin-6-ylamino)butoxy]oxane-3,4,5-triol

C16H25N5O6 (383.1805)


   

(2R,3S,4S,5R,6R)-2-(hydroxymethyl)-6-[6-[[(3S)-4-hydroxy-3-methylbutyl]amino]purin-9-yl]oxane-3,4,5-triol

(2R,3S,4S,5R,6R)-2-(hydroxymethyl)-6-[6-[[(3S)-4-hydroxy-3-methylbutyl]amino]purin-9-yl]oxane-3,4,5-triol

C16H25N5O6 (383.1805)


   

Dihydrozeatin O-beta-D-glucoside

Dihydrozeatin O-beta-D-glucoside

C16H25N5O6 (383.1805)


   

Dihydrozeatin-7-N-glucoside

Dihydrozeatin-7-N-glucoside

C16H25N5O6 (383.1805)


   

7-methylthioheptyldesulfoglucosinolate

7-methylthioheptyldesulfoglucosinolate

C15H29NO6S2 (383.1436)


   

2-acetamido-2-deoxy-3-O-beta-D-galactopyranosyl-beta-D-glucopyranose

2-acetamido-2-deoxy-3-O-beta-D-galactopyranosyl-beta-D-glucopyranose

C14H25NO11 (383.1428)


   

Torrubiellone D

Torrubiellone D

C22H25NO5 (383.1733)


A natural product found in Torrubiella species.

   
   

beta-D-GlcpNAc-(1->3)-beta-D-Galp

beta-D-GlcpNAc-(1->3)-beta-D-Galp

C14H25NO11 (383.1428)


An amino disaccharide comprising N-acetyl-beta-D-glucosamine linked (1->3) to a beta-D-galactose residue.

   

2-(1-Imidazolyl)-4-phenyl-6-(4-phenyl-1-piperazinyl)-1,3,5-triazine

2-(1-Imidazolyl)-4-phenyl-6-(4-phenyl-1-piperazinyl)-1,3,5-triazine

C22H21N7 (383.1858)


   

2-(3,5-Diphenyl-3,4-dihydropyrazol-2-yl)-2-(4-hydroxy-3-methoxyphenyl)acetonitrile

2-(3,5-Diphenyl-3,4-dihydropyrazol-2-yl)-2-(4-hydroxy-3-methoxyphenyl)acetonitrile

C24H21N3O2 (383.1634)


   

7-(Diethylaminomethyl)-1-(4-methoxyphenyl)-2-methyl-3-nitro-6-indolol

7-(Diethylaminomethyl)-1-(4-methoxyphenyl)-2-methyl-3-nitro-6-indolol

C21H25N3O4 (383.1845)


   

3-(1-methyl-1H-pyrrol-2-yl)-N-[(E)-(2,4,5-trimethoxyphenyl)methylidene]-1H-pyrazole-5-carbohydrazide

3-(1-methyl-1H-pyrrol-2-yl)-N-[(E)-(2,4,5-trimethoxyphenyl)methylidene]-1H-pyrazole-5-carbohydrazide

C19H21N5O4 (383.1593)


   

N-Acetyl-Laktosamin

N-Acetyl-Laktosamin

C14H25NO11 (383.1428)


   

6,7-dimethoxy-1-[(E)-2-(2,3,4-trimethoxyphenyl)ethenyl]-3,4-dihydroisoquinoline

6,7-dimethoxy-1-[(E)-2-(2,3,4-trimethoxyphenyl)ethenyl]-3,4-dihydroisoquinoline

C22H25NO5 (383.1733)


   

2-acetamido-2-deoxy-4-O-alpha-D-galactopyranosyl-D-galactopyranose

2-acetamido-2-deoxy-4-O-alpha-D-galactopyranosyl-D-galactopyranose

C14H25NO11 (383.1428)


   

N-acetyl-alpha-D-galactosaminyl-(1->3)-beta-D-galactose

N-acetyl-alpha-D-galactosaminyl-(1->3)-beta-D-galactose

C14H25NO11 (383.1428)


   

Galalpha1-4GlcNAcbeta

Galalpha1-4GlcNAcbeta

C14H25NO11 (383.1428)


   

2-acetamido-2-deoxy-3-O-alpha-D-galactopyranosyl-beta-D-galactopyranose

2-acetamido-2-deoxy-3-O-alpha-D-galactopyranosyl-beta-D-galactopyranose

C14H25NO11 (383.1428)


   

2-acetamido-2-deoxy-3-O-alpha-D-galactopyranosyl-alpha-D-galactopyranose

2-acetamido-2-deoxy-3-O-alpha-D-galactopyranosyl-alpha-D-galactopyranose

C14H25NO11 (383.1428)


   

alpha-D-galactosyl-(1->4)-N-acetylglucosamine

alpha-D-galactosyl-(1->4)-N-acetylglucosamine

C14H25NO11 (383.1428)


   

N-acetyl-alpha-D-galactosaminyl-(1->4)-beta-D-galactose

N-acetyl-alpha-D-galactosaminyl-(1->4)-beta-D-galactose

C14H25NO11 (383.1428)


   
   

N-[2-[4-(dimethylamino)phenyl]-2-(1H-indol-3-yl)ethyl]benzamide

N-[2-[4-(dimethylamino)phenyl]-2-(1H-indol-3-yl)ethyl]benzamide

C25H25N3O (383.1998)


   

beta-D-GalNAc-(1->3)-beta-D-Gal

beta-D-GalNAc-(1->3)-beta-D-Gal

C14H25NO11 (383.1428)


beta-D-GalNAc-(1->3)-D-Gal with beta configuration at the anomeric carbon of the Gal residue.

   

Salmonella outer core terminal disaccharide

Salmonella outer core terminal disaccharide

C14H25NO11 (383.1428)


   

N-butyl-N-methyl-4-[(2-methyl-[1,2,4]triazolo[1,5-c]quinazolin-5-yl)hydrazo]-4-oxobutanamide

N-butyl-N-methyl-4-[(2-methyl-[1,2,4]triazolo[1,5-c]quinazolin-5-yl)hydrazo]-4-oxobutanamide

C19H25N7O2 (383.207)


   

1-[[1-(4-Methoxyphenyl)-3-pyrrolidinyl]methyl]-3-(2,4,6-trimethylphenyl)thiourea

1-[[1-(4-Methoxyphenyl)-3-pyrrolidinyl]methyl]-3-(2,4,6-trimethylphenyl)thiourea

C22H29N3OS (383.2031)


   

1-(4-amino-1,2,5-oxadiazol-3-yl)-5-[(dimethylamino)methyl]-N-(3-phenylpropylideneamino)-4-triazolecarboxamide

1-(4-amino-1,2,5-oxadiazol-3-yl)-5-[(dimethylamino)methyl]-N-(3-phenylpropylideneamino)-4-triazolecarboxamide

C17H21N9O2 (383.1818)


   

6-(2,3-dihydro-1,4-benzodioxin-6-yl)-N-[(3-methylphenyl)methyl]-4-quinazolinamine

6-(2,3-dihydro-1,4-benzodioxin-6-yl)-N-[(3-methylphenyl)methyl]-4-quinazolinamine

C24H21N3O2 (383.1634)


   

2-(3-isopropyloxyphenyl)-N-(pyridin-4-yl)quinoline-4-carboxamide

2-(3-isopropyloxyphenyl)-N-(pyridin-4-yl)quinoline-4-carboxamide

C24H21N3O2 (383.1634)


   

16alpha-Hydroxydehydroepiandrosterone 3-sulfate(1-)

16alpha-Hydroxydehydroepiandrosterone 3-sulfate(1-)

C19H27O6S- (383.1528)


A steroid sulfate oxoanion that is the conjugate base of 16alpha-hydroxydehydroepiandrosterone 3-sulfate, arising from deprotonation of the sulfate OH group; major species at pH 7.3.

   

Beta-1,4-mannose-N-acetylglucosamine

Beta-1,4-mannose-N-acetylglucosamine

C14H25NO11 (383.1428)


COVID info from COVID-19 Disease Map Corona-virus Coronavirus SARS-CoV-2 COVID-19 SARS-CoV COVID19 SARS2 SARS

   

(2,4-Difluorophenyl)-[3-[3-(4-methylphenyl)-1,2,4-oxadiazol-5-yl]-1-piperidinyl]methanone

(2,4-Difluorophenyl)-[3-[3-(4-methylphenyl)-1,2,4-oxadiazol-5-yl]-1-piperidinyl]methanone

C21H19F2N3O2 (383.1445)


   

N-(1-tert-butyl-5-benzimidazolyl)-3,4,5-trimethoxybenzamide

N-(1-tert-butyl-5-benzimidazolyl)-3,4,5-trimethoxybenzamide

C21H25N3O4 (383.1845)


   

N-(1,3-benzodioxol-5-yl)-4-(4-methyl-1-piperidinyl)-3-nitrobenzamide

N-(1,3-benzodioxol-5-yl)-4-(4-methyl-1-piperidinyl)-3-nitrobenzamide

C20H21N3O5 (383.1481)


   

1-[(4-Methoxy-3-phenylmethoxyphenyl)methyl]-4-piperidinecarboxylic acid ethyl ester

1-[(4-Methoxy-3-phenylmethoxyphenyl)methyl]-4-piperidinecarboxylic acid ethyl ester

C23H29NO4 (383.2096)


   

5-(3,4-Dimethoxyphenyl)-2-methyl-4-(4-methyl-1-piperidinyl)thieno[2,3-d]pyrimidine

5-(3,4-Dimethoxyphenyl)-2-methyl-4-(4-methyl-1-piperidinyl)thieno[2,3-d]pyrimidine

C21H25N3O2S (383.1667)


   

N-acetyl-beta-D-glucosaminyl-(1->4)-alpha-D-mannose

N-acetyl-beta-D-glucosaminyl-(1->4)-alpha-D-mannose

C14H25NO11 (383.1428)


An amino disaccharide comprised of N-acetyl-beta-D-glucosamine linked (1->4) to D-mannose.

   

GlcNAc(b1-3)Gal

GlcNAc(b1-3)Gal

C14H25NO11 (383.1428)


   

N-[(2S,3R,4R,5S,6R)-4,5-dihydroxy-6-(hydroxymethyl)-2-[(2S,3S,4S,5S,6R)-2,4,5-trihydroxy-6-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]acetamide

N-[(2S,3R,4R,5S,6R)-4,5-dihydroxy-6-(hydroxymethyl)-2-[(2S,3S,4S,5S,6R)-2,4,5-trihydroxy-6-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]acetamide

C14H25NO11 (383.1428)


   

Galbeta1,6GlcNAc

Galbeta1,6GlcNAc

C14H25NO11 (383.1428)


   

Man(b1-4)a-GlcNAc

Man(b1-4)a-GlcNAc

C14H25NO11 (383.1428)


   

GalNAc(a1-3)a-Gal

GalNAc(a1-3)a-Gal

C14H25NO11 (383.1428)


   

N-[(2R,3R,4R,5S,6R)-4,5-dihydroxy-6-(hydroxymethyl)-2-[[(2R,3R,4S,5R,6R)-3,4,5,6-tetrahydroxyoxan-2-yl]methoxy]oxan-3-yl]acetamide

N-[(2R,3R,4R,5S,6R)-4,5-dihydroxy-6-(hydroxymethyl)-2-[[(2R,3R,4S,5R,6R)-3,4,5,6-tetrahydroxyoxan-2-yl]methoxy]oxan-3-yl]acetamide

C14H25NO11 (383.1428)


   

GlcNAc(b1-6)a-Man

GlcNAc(b1-6)a-Man

C14H25NO11 (383.1428)


   

Gal(b1-6)a-GalNAc

Gal(b1-6)a-GalNAc

C14H25NO11 (383.1428)


   

Gal(b1-4)a-GalNAc

Gal(b1-4)a-GalNAc

C14H25NO11 (383.1428)


   

2-octanoyl-sn-glycero-3-phosphocholine

2-octanoyl-sn-glycero-3-phosphocholine

C16H34NO7P (383.2073)


A 2-acyl-sn-glycero-3-phosphocholine in which the acyl group is specified as octanoyl.

   
   
   
   

N-[(2S,3R,6S)-2-(hydroxymethyl)-6-[2-oxo-2-(2-thiazolylamino)ethyl]-3-oxanyl]-4-oxanecarboxamide

N-[(2S,3R,6S)-2-(hydroxymethyl)-6-[2-oxo-2-(2-thiazolylamino)ethyl]-3-oxanyl]-4-oxanecarboxamide

C17H25N3O5S (383.1515)


   

N-[(2R,3S,6S)-2-(hydroxymethyl)-6-[2-oxo-2-(2-thiazolylamino)ethyl]-3-oxanyl]-4-oxanecarboxamide

N-[(2R,3S,6S)-2-(hydroxymethyl)-6-[2-oxo-2-(2-thiazolylamino)ethyl]-3-oxanyl]-4-oxanecarboxamide

C17H25N3O5S (383.1515)


   

N-[(2R,3R,6R)-2-(hydroxymethyl)-6-[2-oxo-2-(2-thiazolylamino)ethyl]-3-oxanyl]-4-oxanecarboxamide

N-[(2R,3R,6R)-2-(hydroxymethyl)-6-[2-oxo-2-(2-thiazolylamino)ethyl]-3-oxanyl]-4-oxanecarboxamide

C17H25N3O5S (383.1515)


   

N-[[(2R,3R,4R)-4-(hydroxymethyl)-1-(2-methoxy-1-oxoethyl)-3-phenyl-2-azetidinyl]methyl]-N-methyl-4-pyridinecarboxamide

N-[[(2R,3R,4R)-4-(hydroxymethyl)-1-(2-methoxy-1-oxoethyl)-3-phenyl-2-azetidinyl]methyl]-N-methyl-4-pyridinecarboxamide

C21H25N3O4 (383.1845)


   

N-[[(2R,3S,4S)-4-(hydroxymethyl)-1-(2-methoxy-1-oxoethyl)-3-phenyl-2-azetidinyl]methyl]-N-methyl-4-pyridinecarboxamide

N-[[(2R,3S,4S)-4-(hydroxymethyl)-1-(2-methoxy-1-oxoethyl)-3-phenyl-2-azetidinyl]methyl]-N-methyl-4-pyridinecarboxamide

C21H25N3O4 (383.1845)


   

N-[(2R,3S,6R)-2-(hydroxymethyl)-6-[2-oxo-2-(2-thiazolylamino)ethyl]-3-oxanyl]-4-oxanecarboxamide

N-[(2R,3S,6R)-2-(hydroxymethyl)-6-[2-oxo-2-(2-thiazolylamino)ethyl]-3-oxanyl]-4-oxanecarboxamide

C17H25N3O5S (383.1515)


   

N-[(2S,3R,6R)-2-(hydroxymethyl)-6-[2-oxo-2-(2-thiazolylamino)ethyl]-3-oxanyl]-4-oxanecarboxamide

N-[(2S,3R,6R)-2-(hydroxymethyl)-6-[2-oxo-2-(2-thiazolylamino)ethyl]-3-oxanyl]-4-oxanecarboxamide

C17H25N3O5S (383.1515)


   

N-[(2S,3S,6S)-2-(hydroxymethyl)-6-[2-oxo-2-(2-thiazolylamino)ethyl]-3-oxanyl]-4-oxanecarboxamide

N-[(2S,3S,6S)-2-(hydroxymethyl)-6-[2-oxo-2-(2-thiazolylamino)ethyl]-3-oxanyl]-4-oxanecarboxamide

C17H25N3O5S (383.1515)


   

N-[(2S,3S,6R)-2-(hydroxymethyl)-6-[2-oxo-2-(2-thiazolylamino)ethyl]-3-oxanyl]-4-oxanecarboxamide

N-[(2S,3S,6R)-2-(hydroxymethyl)-6-[2-oxo-2-(2-thiazolylamino)ethyl]-3-oxanyl]-4-oxanecarboxamide

C17H25N3O5S (383.1515)


   

N-[(2R,3R,6S)-2-(hydroxymethyl)-6-[2-oxo-2-(2-thiazolylamino)ethyl]-3-oxanyl]-4-oxanecarboxamide

N-[(2R,3R,6S)-2-(hydroxymethyl)-6-[2-oxo-2-(2-thiazolylamino)ethyl]-3-oxanyl]-4-oxanecarboxamide

C17H25N3O5S (383.1515)


   

N-[[(2S,3S,4S)-4-(hydroxymethyl)-1-(2-methoxy-1-oxoethyl)-3-phenyl-2-azetidinyl]methyl]-N-methyl-4-pyridinecarboxamide

N-[[(2S,3S,4S)-4-(hydroxymethyl)-1-(2-methoxy-1-oxoethyl)-3-phenyl-2-azetidinyl]methyl]-N-methyl-4-pyridinecarboxamide

C21H25N3O4 (383.1845)


   

(1R,5S)-7-[4-(3-methylphenyl)phenyl]-N-phenyl-3,6-diazabicyclo[3.1.1]heptane-3-carboxamide

(1R,5S)-7-[4-(3-methylphenyl)phenyl]-N-phenyl-3,6-diazabicyclo[3.1.1]heptane-3-carboxamide

C25H25N3O (383.1998)


   

1-[(1S,5R)-7-[4-(2-methylphenyl)phenyl]-3,6-diazabicyclo[3.1.1]heptan-3-yl]-2-pyridin-4-ylethanone

1-[(1S,5R)-7-[4-(2-methylphenyl)phenyl]-3,6-diazabicyclo[3.1.1]heptan-3-yl]-2-pyridin-4-ylethanone

C25H25N3O (383.1998)


   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   

5-Amino-5-(4-hydroxybenzyl)-6-((2,3,4,5-tetrahydroxypentyl)amino)dihydropyrimidine-2,4-dione(1+)

5-Amino-5-(4-hydroxybenzyl)-6-((2,3,4,5-tetrahydroxypentyl)amino)dihydropyrimidine-2,4-dione(1+)

C16H23N4O7+ (383.1567)


   

7-(Methylthio)heptyldesulfoglucosinolate

7-(Methylthio)heptyldesulfoglucosinolate

C15H29NO6S2 (383.1436)


An omega-(methylsulfany)alkyl desulfoglucosinolate in which the omega-(methylsulfany)alkyl group is specified as 7-(methylsulfanyl)heptyl.

   

(4R,5S,6R)-3-[(3S,5S)-5-(dimethylcarbamoyl)pyrrolidin-3-yl]sulfanyl-6-[(1R)-1-hydroxyethyl]-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid

(4R,5S,6R)-3-[(3S,5S)-5-(dimethylcarbamoyl)pyrrolidin-3-yl]sulfanyl-6-[(1R)-1-hydroxyethyl]-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid

C17H25N3O5S (383.1515)


   

(5S,6Z,8E,10E,12R,14Z)-5,12,20,20,20-pentahydroxyicosa-6,8,10,14-tetraenoate

(5S,6Z,8E,10E,12R,14Z)-5,12,20,20,20-pentahydroxyicosa-6,8,10,14-tetraenoate

C20H31O7- (383.207)


   

(E,8R)-8-[(2R,3R,5R,6S)-3-hydroxy-6-methyl-5-[(E)-2-methylbut-2-enoyl]oxyoxan-2-yl]oxynon-2-enoate

(E,8R)-8-[(2R,3R,5R,6S)-3-hydroxy-6-methyl-5-[(E)-2-methylbut-2-enoyl]oxyoxan-2-yl]oxynon-2-enoate

C20H31O7- (383.207)


   

N-[(2S)-2-hydroxy-2-(1,2,3,4-tetrahydronaphthalen-2-ylamino)ethyl]-6-(oxetan-3-ylamino)pyrimidine-4-carboxamide

N-[(2S)-2-hydroxy-2-(1,2,3,4-tetrahydronaphthalen-2-ylamino)ethyl]-6-(oxetan-3-ylamino)pyrimidine-4-carboxamide

C20H25N5O3 (383.1957)


   

Lnape 4:0/N-6:0

Lnape 4:0/N-6:0

C15H30NO8P (383.1709)


   

Lnape 3:0/N-7:0

Lnape 3:0/N-7:0

C15H30NO8P (383.1709)


   

Lnape 2:0/N-8:0

Lnape 2:0/N-8:0

C15H30NO8P (383.1709)


   

Lnape 8:0/N-2:0

Lnape 8:0/N-2:0

C15H30NO8P (383.1709)


   

Lnape 7:0/N-3:0

Lnape 7:0/N-3:0

C15H30NO8P (383.1709)


   

Lnape 6:0/N-4:0

Lnape 6:0/N-4:0

C15H30NO8P (383.1709)


   

Lnape 5:0/N-5:0

Lnape 5:0/N-5:0

C15H30NO8P (383.1709)


   

[3-[2-Aminoethoxy(hydroxy)phosphoryl]oxy-2-hydroxypropyl] undecanoate

[3-[2-Aminoethoxy(hydroxy)phosphoryl]oxy-2-hydroxypropyl] undecanoate

C16H34NO7P (383.2073)


   

[1-[2-Aminoethoxy(hydroxy)phosphoryl]oxy-3-nonoxypropan-2-yl] acetate

[1-[2-Aminoethoxy(hydroxy)phosphoryl]oxy-3-nonoxypropan-2-yl] acetate

C16H34NO7P (383.2073)


   

[1-[2-Aminoethoxy(hydroxy)phosphoryl]oxy-3-octoxypropan-2-yl] propanoate

[1-[2-Aminoethoxy(hydroxy)phosphoryl]oxy-3-octoxypropan-2-yl] propanoate

C16H34NO7P (383.2073)


   

(3-Acetyloxy-2-pentanoyloxypropyl) 2-(trimethylazaniumyl)ethyl phosphate

(3-Acetyloxy-2-pentanoyloxypropyl) 2-(trimethylazaniumyl)ethyl phosphate

C15H30NO8P (383.1709)


   

(2-Butanoyloxy-3-propanoyloxypropyl) 2-(trimethylazaniumyl)ethyl phosphate

(2-Butanoyloxy-3-propanoyloxypropyl) 2-(trimethylazaniumyl)ethyl phosphate

C15H30NO8P (383.1709)


   

[1-[2-Aminoethoxy(hydroxy)phosphoryl]oxy-3-butanoyloxypropan-2-yl] hexanoate

[1-[2-Aminoethoxy(hydroxy)phosphoryl]oxy-3-butanoyloxypropan-2-yl] hexanoate

C15H30NO8P (383.1709)


   

[1-Acetyloxy-3-[2-aminoethoxy(hydroxy)phosphoryl]oxypropan-2-yl] octanoate

[1-Acetyloxy-3-[2-aminoethoxy(hydroxy)phosphoryl]oxypropan-2-yl] octanoate

C15H30NO8P (383.1709)


   

[3-[2-Aminoethoxy(hydroxy)phosphoryl]oxy-2-pentanoyloxypropyl] pentanoate

[3-[2-Aminoethoxy(hydroxy)phosphoryl]oxy-2-pentanoyloxypropyl] pentanoate

C15H30NO8P (383.1709)


   

[1-[2-Aminoethoxy(hydroxy)phosphoryl]oxy-3-propanoyloxypropan-2-yl] heptanoate

[1-[2-Aminoethoxy(hydroxy)phosphoryl]oxy-3-propanoyloxypropan-2-yl] heptanoate

C15H30NO8P (383.1709)


   
   

7-(alpha-D-glucosyl)dihydrozeatin

7-(alpha-D-glucosyl)dihydrozeatin

C16H25N5O6 (383.1805)


An N-glycosyldihydrozeatin in which the glycosyl fragment is an alpha-D-glucopyranosyl residue located at position 7.

   

3-[5-(Dimethylcarbamoyl)pyrrolidin-3-yl]sulfanyl-6-(1-hydroxyethyl)-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid

3-[5-(Dimethylcarbamoyl)pyrrolidin-3-yl]sulfanyl-6-(1-hydroxyethyl)-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid

C17H25N3O5S (383.1515)


   

CID 85115123

CID 85115123

C18H25NO8 (383.158)


   

1-octanoyl-sn-glycero-3-phosphocholine

1-octanoyl-sn-glycero-3-phosphocholine

C16H34NO7P (383.2073)


   

(3R)-1,2-didehydro-3-hydroxy-16-methoxy-2,3-dihydrotabersoninium

(3R)-1,2-didehydro-3-hydroxy-16-methoxy-2,3-dihydrotabersoninium

C22H27N2O4 (383.1971)


An indole alkaloid cation that is the conjugate acid of (3R)-1,2-didehydro-3-hydroxy-16-methoxy-2,3-dihydrotabersonine, obtained by protonation of the tertiary amino group. Major species at pH 7.3.

   

PE(10:0)

PE(4:0_6:0)

C15H30NO8P (383.1709)


Provides by LipidSearch Vendor. © Copyright 2006-2024 Thermo Fisher Scientific Inc. All rights reserved

   
   

Methylthioheptyl-desulfoglucosinolate

Methylthioheptyl-desulfoglucosinolate

C15H29NO6S2 (383.1436)


   
   
   

ST 21:5;O2;Gly

ST 21:5;O2;Gly

C23H29NO4 (383.2096)


   

BAY1125976

BAY1125976

C23H21N5O (383.1746)


BAY1125976 is a selective allosteric Akt1/Akt2 inhibitor; inhibits Akt1 and Akt2 activity with IC50 values of 5.2 nM and 18 nM at 10 μM ATP, respectively.

   

CC214-2

CC214-2

C20H25N5O3 (383.1957)


CC214-2 is an oral active and selective mTOR kinase inhibitor. CC214-2 targets to both of mTORC1 (pS6) and mTORC2 (pAktS473). CC214-2 induces autophagy, which is a potential target for host-directed therapy (HDT) in tuberculosis. CC214-2 exhibits synergistic bactericidal and sterilizing activity agasinst tuberculosis (TB), and shortens the treatment duration. CC214-2 also inhibits Rapamycin (HY-10219)-resistant signaling and the growth of glioblastomas in vitro and in vivo[1][2]. CC214-2 is an oral active and selective mTOR kinase inhibitor. CC214-2 targets to both of mTORC1 (pS6) and mTORC2 (pAktS473). CC214-2 induces autophagy, which is a potential target for host-directed therapy (HDT) in tuberculosis. CC214-2 exhibits synergistic bactericidal and sterilizing activity agasinst tuberculosis (TB), and shortens the treatment duration. CC214-2 also inhibits Rapamycin (HY-10219)-resistant signaling and the growth of glioblastomas in vitro and in vivo[1][2].

   

Dehydrocorydaline (hydroxyl)

Dehydrocorydaline (hydroxyl)

C22H25NO5 (383.1733)


Dehydrocorydaline (13-Methylpalmatine) hydroxyl is an alkaloid that regulates protein expression of Bax, Bcl-2; activates caspase-7, caspase-8, and inactivates PARP. Dehydrocorydaline hydroxyl elevates p38 MAPK activation. Anti-inflammatory and anti-cancer activities. Dehydrocorydaline hydroxyl shows strong anti-malarial effects (IC50=38 nM), and low cytotoxicity (cell viability > 90\%) using P. falciparum 3D7 strain.

   

methyl 18-formyl-19-hydroxy-14-methyl-12-azahexacyclo[10.6.1.1¹,⁴.0¹⁰,¹⁸.0¹⁵,¹⁹.0⁷,²⁰]icosa-7(20),16-diene-3-carboxylate

methyl 18-formyl-19-hydroxy-14-methyl-12-azahexacyclo[10.6.1.1¹,⁴.0¹⁰,¹⁸.0¹⁵,¹⁹.0⁷,²⁰]icosa-7(20),16-diene-3-carboxylate

C23H29NO4 (383.2096)


   

(1r,4s,5r,6r,7r,11z)-4-ethyl-5,7-dihydroxy-6,7,14-trimethyl-2,9-dioxa-14-azabicyclo[9.5.1]heptadec-11-ene-3,8,17-trione

(1r,4s,5r,6r,7r,11z)-4-ethyl-5,7-dihydroxy-6,7,14-trimethyl-2,9-dioxa-14-azabicyclo[9.5.1]heptadec-11-ene-3,8,17-trione

C19H29NO7 (383.1944)


   

[7-(acetyloxy)-5,6,7,7a-tetrahydro-3h-pyrrolizin-1-yl]methyl 3-(acetyloxy)-2-hydroxy-2-isopropylbutanoate

[7-(acetyloxy)-5,6,7,7a-tetrahydro-3h-pyrrolizin-1-yl]methyl 3-(acetyloxy)-2-hydroxy-2-isopropylbutanoate

C19H29NO7 (383.1944)


   

n-[(2s,3s,4s,5r,6r)-6-{[(2s,3s,4r,5s)-1,4-diamino-2,5,6-trihydroxyhexan-3-yl]oxy}-4,5-dihydroxy-2-(hydroxymethyl)oxan-3-yl]ethanimidic acid

n-[(2s,3s,4s,5r,6r)-6-{[(2s,3s,4r,5s)-1,4-diamino-2,5,6-trihydroxyhexan-3-yl]oxy}-4,5-dihydroxy-2-(hydroxymethyl)oxan-3-yl]ethanimidic acid

C14H29N3O9 (383.1904)


   

9-hydroxy-9-(1-hydroxyethyl)-7-(hydroxymethyl)-5-methyl-3,6,11-trioxa-15-azatetracyclo[10.5.1.0⁵,⁷.0¹⁵,¹⁸]octadec-1(17)-ene-4,10-dione

9-hydroxy-9-(1-hydroxyethyl)-7-(hydroxymethyl)-5-methyl-3,6,11-trioxa-15-azatetracyclo[10.5.1.0⁵,⁷.0¹⁵,¹⁸]octadec-1(17)-ene-4,10-dione

C18H25NO8 (383.158)


   

1-(2-hydroxy-1-methoxypropyl)-3-methoxy-2-methyl-6-(3-methylbut-2-en-1-yl)-9h-carbazol-4-ol

1-(2-hydroxy-1-methoxypropyl)-3-methoxy-2-methyl-6-(3-methylbut-2-en-1-yl)-9h-carbazol-4-ol

C23H29NO4 (383.2096)


   

7-(hepta-1,3,5-trien-1-yl)-2,6,8-trioxatricyclo[5.3.1.0⁴,¹¹]undecan-4-yl 2-aminobenzoate

7-(hepta-1,3,5-trien-1-yl)-2,6,8-trioxatricyclo[5.3.1.0⁴,¹¹]undecan-4-yl 2-aminobenzoate

C22H25NO5 (383.1733)


   

(3s,4s)-3-methoxy-4-(4-methoxyphenyl)-6-(3-methylbut-2-en-1-yl)-3h-quinoline-2,4,5-triol

(3s,4s)-3-methoxy-4-(4-methoxyphenyl)-6-(3-methylbut-2-en-1-yl)-3h-quinoline-2,4,5-triol

C22H25NO5 (383.1733)


   

4-({2-imino-5-[(4-methoxyphenyl)methyl]-3-methyl-1h-imidazol-4-yl}methyl)-2,6-dimethoxyphenol

4-({2-imino-5-[(4-methoxyphenyl)methyl]-3-methyl-1h-imidazol-4-yl}methyl)-2,6-dimethoxyphenol

C21H25N3O4 (383.1845)


   

3-[2-(7-chloro-3-hydroxy-5,5,8a-trimethyl-2-methylidene-hexahydro-1h-naphthalen-1-yl)-1-hydroxyethyl]-5-hydroxy-3,4-dihydropyrrol-2-one

3-[2-(7-chloro-3-hydroxy-5,5,8a-trimethyl-2-methylidene-hexahydro-1h-naphthalen-1-yl)-1-hydroxyethyl]-5-hydroxy-3,4-dihydropyrrol-2-one

C20H30ClNO4 (383.1863)


   

n-[2-(4-{[(2e)-3-(5,5-dimethyl-4-oxofuran-2-yl)but-2-en-1-yl]oxy}phenyl)ethyl]-3-methylbut-2-enimidic acid

n-[2-(4-{[(2e)-3-(5,5-dimethyl-4-oxofuran-2-yl)but-2-en-1-yl]oxy}phenyl)ethyl]-3-methylbut-2-enimidic acid

C23H29NO4 (383.2096)


   

1-hydroxy-3,5,6-trimethoxy-10-methyl-4-(3-methylbut-2-en-1-yl)acridin-9-one

1-hydroxy-3,5,6-trimethoxy-10-methyl-4-(3-methylbut-2-en-1-yl)acridin-9-one

C22H25NO5 (383.1733)


   

3-{[2,6-dihydroxy-3-(3-methylbut-2-en-1-yl)indol-3-yl]methyl}-1-hydroxy-3h,6h,7h,8h,8ah-pyrrolo[1,2-a]pyrazin-4-one

3-{[2,6-dihydroxy-3-(3-methylbut-2-en-1-yl)indol-3-yl]methyl}-1-hydroxy-3h,6h,7h,8h,8ah-pyrrolo[1,2-a]pyrazin-4-one

C21H25N3O4 (383.1845)


   

(1r,2s,3r,5r,10s)-17-(methoxycarbonyl)-2,6-dimethyl-20-oxo-8-azahexacyclo[11.5.1.1¹,⁵.0²,¹⁰.0³,⁸.0¹⁶,¹⁹]icosa-13(19),16-dien-8-ium-8-olate

(1r,2s,3r,5r,10s)-17-(methoxycarbonyl)-2,6-dimethyl-20-oxo-8-azahexacyclo[11.5.1.1¹,⁵.0²,¹⁰.0³,⁸.0¹⁶,¹⁹]icosa-13(19),16-dien-8-ium-8-olate

C23H29NO4 (383.2096)


   

(3s,5r,8r,14s,18r)-5,7-dimethyl-12-methylidene-10,16-dioxo-7-azahexacyclo[9.6.2.0¹,⁸.0⁵,¹⁷.0⁹,¹⁴.0¹⁴,¹⁸]nonadecan-3-yl acetate

(3s,5r,8r,14s,18r)-5,7-dimethyl-12-methylidene-10,16-dioxo-7-azahexacyclo[9.6.2.0¹,⁸.0⁵,¹⁷.0⁹,¹⁴.0¹⁴,¹⁸]nonadecan-3-yl acetate

C23H29NO4 (383.2096)


   

dimethyl(2-{1,2,3-trimethoxy-9h-phenanthro[2,3-d][1,3]dioxol-4-yl}ethyl)amine

dimethyl(2-{1,2,3-trimethoxy-9h-phenanthro[2,3-d][1,3]dioxol-4-yl}ethyl)amine

C22H25NO5 (383.1733)


   

(1s,9r,14s)-15-hydroxy-2,11-dimethoxy-14-methyl-9-(2-methylbut-3-en-2-yl)-2,13,16-triazatetracyclo[7.7.0.0¹,¹³.0³,⁸]hexadeca-3,5,7,10,15-pentaen-12-one

(1s,9r,14s)-15-hydroxy-2,11-dimethoxy-14-methyl-9-(2-methylbut-3-en-2-yl)-2,13,16-triazatetracyclo[7.7.0.0¹,¹³.0³,⁸]hexadeca-3,5,7,10,15-pentaen-12-one

C21H25N3O4 (383.1845)


   

methyl (1r,3r,4r,10s,14s,15r,18r,19r)-18-formyl-19-hydroxy-14-methyl-12-azahexacyclo[10.6.1.1¹,⁴.0¹⁰,¹⁸.0¹⁵,¹⁹.0⁷,²⁰]icosa-7(20),16-diene-3-carboxylate

methyl (1r,3r,4r,10s,14s,15r,18r,19r)-18-formyl-19-hydroxy-14-methyl-12-azahexacyclo[10.6.1.1¹,⁴.0¹⁰,¹⁸.0¹⁵,¹⁹.0⁷,²⁰]icosa-7(20),16-diene-3-carboxylate

C23H29NO4 (383.2096)


   

methyl (1r,2s,3r,5r,6s,10s)-2,6-dimethyl-21-oxo-14-oxa-8-azahexacyclo[11.6.1.1¹,⁵.0²,¹⁰.0³,⁸.0¹⁷,²⁰]henicosa-13(20),17-diene-18-carboxylate

methyl (1r,2s,3r,5r,6s,10s)-2,6-dimethyl-21-oxo-14-oxa-8-azahexacyclo[11.6.1.1¹,⁵.0²,¹⁰.0³,⁸.0¹⁷,²⁰]henicosa-13(20),17-diene-18-carboxylate

C23H29NO4 (383.2096)


   
   

8-[4-(1h-indol-3-yl)-2-oxobut-3-en-1-ylidene]-3,9-diazatricyclo[8.4.0.0³,⁷]tetradeca-1(14),10,12-trien-2-one

8-[4-(1h-indol-3-yl)-2-oxobut-3-en-1-ylidene]-3,9-diazatricyclo[8.4.0.0³,⁷]tetradeca-1(14),10,12-trien-2-one

C24H21N3O2 (383.1634)


   

4-(hydroxymethyl)-7-methyl-8-[3-methyl-3-(3-methylpentyl)oxiran-2-yl]-9h-carbazole-1,6-diol

4-(hydroxymethyl)-7-methyl-8-[3-methyl-3-(3-methylpentyl)oxiran-2-yl]-9h-carbazole-1,6-diol

C23H29NO4 (383.2096)


   

(3r,3as,9as)-9a-methyl-3-octanoyl-6-[(1e)-prop-1-en-1-yl]-3h,3ah,4h-furo[3,2-g]isoquinoline-2,9-dione

(3r,3as,9as)-9a-methyl-3-octanoyl-6-[(1e)-prop-1-en-1-yl]-3h,3ah,4h-furo[3,2-g]isoquinoline-2,9-dione

C23H29NO4 (383.2096)


   

n-[2-(4-{[3-(5,5-dimethyl-4-oxofuran-2-yl)but-2-en-1-yl]oxy}phenyl)ethyl]-3-methylbut-2-enimidic acid

n-[2-(4-{[3-(5,5-dimethyl-4-oxofuran-2-yl)but-2-en-1-yl]oxy}phenyl)ethyl]-3-methylbut-2-enimidic acid

C23H29NO4 (383.2096)


   

(1s,4s,7s,11r)-7-[(1e,3e,5e)-hepta-1,3,5-trien-1-yl]-2,6,8-trioxatricyclo[5.3.1.0⁴,¹¹]undecan-4-yl 2-aminobenzoate

(1s,4s,7s,11r)-7-[(1e,3e,5e)-hepta-1,3,5-trien-1-yl]-2,6,8-trioxatricyclo[5.3.1.0⁴,¹¹]undecan-4-yl 2-aminobenzoate

C22H25NO5 (383.1733)


   

13-(isopropoxymethyl)-3,13,23-triazahexacyclo[14.7.0.0²,¹⁰.0⁴,⁹.0¹¹,¹⁵.0¹⁷,²²]tricosa-1(16),2(10),4(9),5,7,11(15),17(22),18,20-nonaen-12-one

13-(isopropoxymethyl)-3,13,23-triazahexacyclo[14.7.0.0²,¹⁰.0⁴,⁹.0¹¹,¹⁵.0¹⁷,²²]tricosa-1(16),2(10),4(9),5,7,11(15),17(22),18,20-nonaen-12-one

C24H21N3O2 (383.1634)


   

n-[(3s,6r)-6-{[(2s,3s,4r,5s)-1,4-diamino-2,5,6-trihydroxyhexan-3-yl]oxy}-4,5-dihydroxy-2-(hydroxymethyl)oxan-3-yl]ethanimidic acid

n-[(3s,6r)-6-{[(2s,3s,4r,5s)-1,4-diamino-2,5,6-trihydroxyhexan-3-yl]oxy}-4,5-dihydroxy-2-(hydroxymethyl)oxan-3-yl]ethanimidic acid

C14H29N3O9 (383.1904)


   

(12s,16s,17s,19r,20s)-17,22-dihydroxy-16,20-dimethyl-4-oxa-14-azahexacyclo[15.4.1.0²,⁷.0⁸,²¹.0¹²,²⁰.0¹⁴,¹⁹]docosa-1(22),2(7),8(21)-triene-3,9-dione

(12s,16s,17s,19r,20s)-17,22-dihydroxy-16,20-dimethyl-4-oxa-14-azahexacyclo[15.4.1.0²,⁷.0⁸,²¹.0¹²,²⁰.0¹⁴,¹⁹]docosa-1(22),2(7),8(21)-triene-3,9-dione

C22H25NO5 (383.1733)


   

(6r,7r)-6',7'-dimethoxy-2',6-dimethyl-2,3',4',8-tetrahydrospiro[indeno[4,5-d][1,3]dioxole-7,1'-isoquinolin]-6-ol

(6r,7r)-6',7'-dimethoxy-2',6-dimethyl-2,3',4',8-tetrahydrospiro[indeno[4,5-d][1,3]dioxole-7,1'-isoquinolin]-6-ol

C22H25NO5 (383.1733)


   

(1r,2s,3r,5r,6s,8r,10s)-17-(methoxycarbonyl)-2,6-dimethyl-20-oxo-8-azahexacyclo[11.5.1.1¹,⁵.0²,¹⁰.0³,⁸.0¹⁶,¹⁹]icosa-13(19),16-dien-8-ium-8-olate

(1r,2s,3r,5r,6s,8r,10s)-17-(methoxycarbonyl)-2,6-dimethyl-20-oxo-8-azahexacyclo[11.5.1.1¹,⁵.0²,¹⁰.0³,⁸.0¹⁶,¹⁹]icosa-13(19),16-dien-8-ium-8-olate

C23H29NO4 (383.2096)


   

(5s,7r,9r,12r,18r)-9-hydroxy-9-[(1s)-1-hydroxyethyl]-7-(hydroxymethyl)-5-methyl-3,6,11-trioxa-15-azatetracyclo[10.5.1.0⁵,⁷.0¹⁵,¹⁸]octadec-1(17)-ene-4,10-dione

(5s,7r,9r,12r,18r)-9-hydroxy-9-[(1s)-1-hydroxyethyl]-7-(hydroxymethyl)-5-methyl-3,6,11-trioxa-15-azatetracyclo[10.5.1.0⁵,⁷.0¹⁵,¹⁸]octadec-1(17)-ene-4,10-dione

C18H25NO8 (383.158)


   

4-[(2e,4e,6e)-8-ethyl-1,9-dihydroxynona-2,4,6-trien-1-ylidene]-5-hydroxy-2-[(4-hydroxyphenyl)methyl]-2h-pyrrol-3-one

4-[(2e,4e,6e)-8-ethyl-1,9-dihydroxynona-2,4,6-trien-1-ylidene]-5-hydroxy-2-[(4-hydroxyphenyl)methyl]-2h-pyrrol-3-one

C22H25NO5 (383.1733)


   

(4z)-4-[(2e,4e,6e)-8-ethyl-1,9-dihydroxynona-2,4,6-trien-1-ylidene]-5-hydroxy-2-[(4-hydroxyphenyl)methyl]-2h-pyrrol-3-one

(4z)-4-[(2e,4e,6e)-8-ethyl-1,9-dihydroxynona-2,4,6-trien-1-ylidene]-5-hydroxy-2-[(4-hydroxyphenyl)methyl]-2h-pyrrol-3-one

C22H25NO5 (383.1733)


   

2-(3,4-dimethoxyphenyl)-5,8-dimethoxy-3-propyl-1h-quinolin-4-one

2-(3,4-dimethoxyphenyl)-5,8-dimethoxy-3-propyl-1h-quinolin-4-one

C22H25NO5 (383.1733)


   

3-{[2,6-dihydroxy-3-(2-methylbut-3-en-2-yl)indol-3-yl]methyl}-1-hydroxy-3h,6h,7h,8h,8ah-pyrrolo[1,2-a]pyrazin-4-one

3-{[2,6-dihydroxy-3-(2-methylbut-3-en-2-yl)indol-3-yl]methyl}-1-hydroxy-3h,6h,7h,8h,8ah-pyrrolo[1,2-a]pyrazin-4-one

C21H25N3O4 (383.1845)


   

(4as,6s,7r,7as)-4-(methoxycarbonyl)-7-methyl-1h,2h,4ah,5h,6h,7h,7ah-cyclopenta[c]pyridin-6-yl (1s)-1-methyl-1,2-dihydro-2,7-naphthyridine-4-carboxylate

(4as,6s,7r,7as)-4-(methoxycarbonyl)-7-methyl-1h,2h,4ah,5h,6h,7h,7ah-cyclopenta[c]pyridin-6-yl (1s)-1-methyl-1,2-dihydro-2,7-naphthyridine-4-carboxylate

C21H25N3O4 (383.1845)


   

(1s,4r,5s,6s,9r,10r,13r)-6-hydroxy-5,9-dimethyl-12-oxo-14-azapentacyclo[11.7.1.0¹,¹⁰.0⁴,⁹.0¹⁵,²⁰]henicosa-15,17,19-triene-5-carboxylic acid

(1s,4r,5s,6s,9r,10r,13r)-6-hydroxy-5,9-dimethyl-12-oxo-14-azapentacyclo[11.7.1.0¹,¹⁰.0⁴,⁹.0¹⁵,²⁰]henicosa-15,17,19-triene-5-carboxylic acid

C23H29NO4 (383.2096)


   

4-(methoxycarbonyl)-7-methyl-1h,2h,4ah,5h,6h,7h,7ah-cyclopenta[c]pyridin-6-yl 1-methyl-1,2-dihydro-2,7-naphthyridine-4-carboxylate

4-(methoxycarbonyl)-7-methyl-1h,2h,4ah,5h,6h,7h,7ah-cyclopenta[c]pyridin-6-yl 1-methyl-1,2-dihydro-2,7-naphthyridine-4-carboxylate

C21H25N3O4 (383.1845)


   

n-[(4-{[(2s,3r,4s,5r,6s)-5-(acetyloxy)-3,4-dihydroxy-6-methyloxan-2-yl]oxy}phenyl)methyl]ethoxycarboximidic acid

n-[(4-{[(2s,3r,4s,5r,6s)-5-(acetyloxy)-3,4-dihydroxy-6-methyloxan-2-yl]oxy}phenyl)methyl]ethoxycarboximidic acid

C18H25NO8 (383.158)


   

[(7r,7ar)-7-(acetyloxy)-5,6,7,7a-tetrahydro-3h-pyrrolizin-1-yl]methyl (2s)-2-[(1s)-1-(acetyloxy)ethyl]-2-hydroxy-3-methylbutanoate

[(7r,7ar)-7-(acetyloxy)-5,6,7,7a-tetrahydro-3h-pyrrolizin-1-yl]methyl (2s)-2-[(1s)-1-(acetyloxy)ethyl]-2-hydroxy-3-methylbutanoate

C19H29NO7 (383.1944)


   

9a-methyl-3-octanoyl-6-(prop-1-en-1-yl)-3h,3ah,4h-furo[3,2-g]isoquinoline-2,9-dione

9a-methyl-3-octanoyl-6-(prop-1-en-1-yl)-3h,3ah,4h-furo[3,2-g]isoquinoline-2,9-dione

C23H29NO4 (383.2096)


   

6',7'-dihydroxy-6'-(hydroxymethyl)-3,7'-dimethyl-2',9'-dioxa-14'-azaspiro[oxirane-2,4'-tricyclo[9.5.1.0¹⁴,¹⁷]heptadecan]-11'-ene-3',8'-dione

6',7'-dihydroxy-6'-(hydroxymethyl)-3,7'-dimethyl-2',9'-dioxa-14'-azaspiro[oxirane-2,4'-tricyclo[9.5.1.0¹⁴,¹⁷]heptadecan]-11'-ene-3',8'-dione

C18H25NO8 (383.158)


   

2-[(3e,5e)-3,5-dimethyl-6-(4-nitrophenyl)hexa-3,5-dien-1-yl]-6-methoxy-3,5-dimethylpyran-4-one

2-[(3e,5e)-3,5-dimethyl-6-(4-nitrophenyl)hexa-3,5-dien-1-yl]-6-methoxy-3,5-dimethylpyran-4-one

C22H25NO5 (383.1733)


   

(1'r,2r,3r,6'r,7's,17'r)-6',7'-dihydroxy-6'-(hydroxymethyl)-3,7'-dimethyl-2',9'-dioxa-14'-azaspiro[oxirane-2,4'-tricyclo[9.5.1.0¹⁴,¹⁷]heptadecan]-11'-ene-3',8'-dione

(1'r,2r,3r,6'r,7's,17'r)-6',7'-dihydroxy-6'-(hydroxymethyl)-3,7'-dimethyl-2',9'-dioxa-14'-azaspiro[oxirane-2,4'-tricyclo[9.5.1.0¹⁴,¹⁷]heptadecan]-11'-ene-3',8'-dione

C18H25NO8 (383.158)


   

[(2s,3s,5r,8r)-5,9,9-trimethyl-19-oxo-4,10-dioxa-18-azapentacyclo[9.8.0.0²,⁸.0³,⁵.0¹²,¹⁷]nonadeca-1(11),12,14,16-tetraen-18-yl]methyl acetate

[(2s,3s,5r,8r)-5,9,9-trimethyl-19-oxo-4,10-dioxa-18-azapentacyclo[9.8.0.0²,⁸.0³,⁵.0¹²,¹⁷]nonadeca-1(11),12,14,16-tetraen-18-yl]methyl acetate

C22H25NO5 (383.1733)


   

4-ethyl-5,7-dihydroxy-6,7,14-trimethyl-2,9-dioxa-14-azabicyclo[9.5.1]heptadec-11-ene-3,8,17-trione

4-ethyl-5,7-dihydroxy-6,7,14-trimethyl-2,9-dioxa-14-azabicyclo[9.5.1]heptadec-11-ene-3,8,17-trione

C19H29NO7 (383.1944)


   

6',7'-dimethoxy-2',6-dimethyl-2,3',4',8-tetrahydrospiro[indeno[4,5-d][1,3]dioxole-7,1'-isoquinolin]-6-ol

6',7'-dimethoxy-2',6-dimethyl-2,3',4',8-tetrahydrospiro[indeno[4,5-d][1,3]dioxole-7,1'-isoquinolin]-6-ol

C22H25NO5 (383.1733)


   

(1r,3s,5r,8r,9s,11s,14s,17r,18r)-5,7-dimethyl-12-methylidene-10,16-dioxo-7-azahexacyclo[9.6.2.0¹,⁸.0⁵,¹⁷.0⁹,¹⁴.0¹⁴,¹⁸]nonadecan-3-yl acetate

(1r,3s,5r,8r,9s,11s,14s,17r,18r)-5,7-dimethyl-12-methylidene-10,16-dioxo-7-azahexacyclo[9.6.2.0¹,⁸.0⁵,¹⁷.0⁹,¹⁴.0¹⁴,¹⁸]nonadecan-3-yl acetate

C23H29NO4 (383.2096)


   

(12bs)-3,4,10,11-tetramethoxy-13,13-dimethyl-5,7,8,12b-tetrahydro-6-azatetraphene

(12bs)-3,4,10,11-tetramethoxy-13,13-dimethyl-5,7,8,12b-tetrahydro-6-azatetraphene

C23H29NO4 (383.2096)


   

4-(8-ethyl-1,9-dihydroxynona-2,4,6-trien-1-ylidene)-5-hydroxy-2-[(4-hydroxyphenyl)methyl]-2h-pyrrol-3-one

4-(8-ethyl-1,9-dihydroxynona-2,4,6-trien-1-ylidene)-5-hydroxy-2-[(4-hydroxyphenyl)methyl]-2h-pyrrol-3-one

C22H25NO5 (383.1733)


   
   

(3r)-3-[(1s)-2-[(1r,3s,4as,7s,8ar)-7-chloro-3-hydroxy-5,5,8a-trimethyl-2-methylidene-hexahydro-1h-naphthalen-1-yl]-1-hydroxyethyl]-5-hydroxy-3,4-dihydropyrrol-2-one

(3r)-3-[(1s)-2-[(1r,3s,4as,7s,8ar)-7-chloro-3-hydroxy-5,5,8a-trimethyl-2-methylidene-hexahydro-1h-naphthalen-1-yl]-1-hydroxyethyl]-5-hydroxy-3,4-dihydropyrrol-2-one

C20H30ClNO4 (383.1863)


   

(12s,16r,17s,19r,20s)-17,22-dihydroxy-16,20-dimethyl-4-oxa-14-azahexacyclo[15.4.1.0²,⁷.0⁸,²¹.0¹²,²⁰.0¹⁴,¹⁹]docosa-1(22),2(7),8(21)-triene-3,9-dione

(12s,16r,17s,19r,20s)-17,22-dihydroxy-16,20-dimethyl-4-oxa-14-azahexacyclo[15.4.1.0²,⁷.0⁸,²¹.0¹²,²⁰.0¹⁴,¹⁹]docosa-1(22),2(7),8(21)-triene-3,9-dione

C22H25NO5 (383.1733)


   

(3r)-3-[(1s)-2-[(1r,3s,4as,7s,8as)-7-chloro-3-hydroxy-5,5,8a-trimethyl-2-methylidene-hexahydro-1h-naphthalen-1-yl]-1-hydroxyethyl]-5-hydroxy-3,4-dihydropyrrol-2-one

(3r)-3-[(1s)-2-[(1r,3s,4as,7s,8as)-7-chloro-3-hydroxy-5,5,8a-trimethyl-2-methylidene-hexahydro-1h-naphthalen-1-yl]-1-hydroxyethyl]-5-hydroxy-3,4-dihydropyrrol-2-one

C20H30ClNO4 (383.1863)


   

4,6-dihydroxy-2',5',5',8'a-tetramethyl-2',3,3',4',4'a,7',8,8'-octahydrospiro[furo[2,3-e]isoindole-2,1'-naphthalen]-6'-one

4,6-dihydroxy-2',5',5',8'a-tetramethyl-2',3,3',4',4'a,7',8,8'-octahydrospiro[furo[2,3-e]isoindole-2,1'-naphthalen]-6'-one

C23H29NO4 (383.2096)


   

tert-butyl 3-{[(3s,8as)-1-hydroxy-4-oxo-3h,6h,7h,8h,8ah-pyrrolo[1,2-a]pyrazin-3-yl]methyl}indole-1-carboxylate

tert-butyl 3-{[(3s,8as)-1-hydroxy-4-oxo-3h,6h,7h,8h,8ah-pyrrolo[1,2-a]pyrazin-3-yl]methyl}indole-1-carboxylate

C21H25N3O4 (383.1845)


   

6-({2-imino-5-[(4-methoxyphenyl)methyl]-3-methyl-1h-imidazol-4-yl}methyl)-2,3-dimethoxyphenol

6-({2-imino-5-[(4-methoxyphenyl)methyl]-3-methyl-1h-imidazol-4-yl}methyl)-2,3-dimethoxyphenol

C21H25N3O4 (383.1845)


   

(3s,8as)-3-{[(3s)-2,6-dihydroxy-3-(2-methylbut-3-en-2-yl)indol-3-yl]methyl}-1-hydroxy-3h,6h,7h,8h,8ah-pyrrolo[1,2-a]pyrazin-4-one

(3s,8as)-3-{[(3s)-2,6-dihydroxy-3-(2-methylbut-3-en-2-yl)indol-3-yl]methyl}-1-hydroxy-3h,6h,7h,8h,8ah-pyrrolo[1,2-a]pyrazin-4-one

C21H25N3O4 (383.1845)


   

(1r,2s,3r,5r,6s,10s)-17-(methoxycarbonyl)-2,6-dimethyl-20-oxo-8-azahexacyclo[11.5.1.1¹,⁵.0²,¹⁰.0³,⁸.0¹⁶,¹⁹]icosa-13(19),16-dien-8-ium-8-olate

(1r,2s,3r,5r,6s,10s)-17-(methoxycarbonyl)-2,6-dimethyl-20-oxo-8-azahexacyclo[11.5.1.1¹,⁵.0²,¹⁰.0³,⁸.0¹⁶,¹⁹]icosa-13(19),16-dien-8-ium-8-olate

C23H29NO4 (383.2096)


   

(2s,3s,4r,5s,6r)-2-(hydroxymethyl)-6-({[(2r)-4-(3h-purin-6-ylamino)butan-2-yl]oxy}methyl)oxane-3,4,5-triol

(2s,3s,4r,5s,6r)-2-(hydroxymethyl)-6-({[(2r)-4-(3h-purin-6-ylamino)butan-2-yl]oxy}methyl)oxane-3,4,5-triol

C16H25N5O6 (383.1805)


   

4,5,14,15,16-pentamethoxy-10-methyl-10-azatetracyclo[7.7.1.0²,⁷.0¹³,¹⁷]heptadeca-1(17),2(7),3,5,8,13,15-heptaene

4,5,14,15,16-pentamethoxy-10-methyl-10-azatetracyclo[7.7.1.0²,⁷.0¹³,¹⁷]heptadeca-1(17),2(7),3,5,8,13,15-heptaene

C22H25NO5 (383.1733)


   

(2r,2'r,4'ar,8'as)-4,6-dihydroxy-2',5',5',8'a-tetramethyl-2',3,3',4',4'a,7',8,8'-octahydrospiro[furo[2,3-e]isoindole-2,1'-naphthalen]-6'-one

(2r,2'r,4'ar,8'as)-4,6-dihydroxy-2',5',5',8'a-tetramethyl-2',3,3',4',4'a,7',8,8'-octahydrospiro[furo[2,3-e]isoindole-2,1'-naphthalen]-6'-one

C23H29NO4 (383.2096)


   

15-hydroxy-2,11-dimethoxy-14-methyl-9-(2-methylbut-3-en-2-yl)-2,13,16-triazatetracyclo[7.7.0.0¹,¹³.0³,⁸]hexadeca-3,5,7,10,15-pentaen-12-one

15-hydroxy-2,11-dimethoxy-14-methyl-9-(2-methylbut-3-en-2-yl)-2,13,16-triazatetracyclo[7.7.0.0¹,¹³.0³,⁸]hexadeca-3,5,7,10,15-pentaen-12-one

C21H25N3O4 (383.1845)


   

(7s,8z)-8-[(3e)-4-(1h-indol-3-yl)-2-oxobut-3-en-1-ylidene]-3,9-diazatricyclo[8.4.0.0³,⁷]tetradeca-1(14),10,12-trien-2-one

(7s,8z)-8-[(3e)-4-(1h-indol-3-yl)-2-oxobut-3-en-1-ylidene]-3,9-diazatricyclo[8.4.0.0³,⁷]tetradeca-1(14),10,12-trien-2-one

C24H21N3O2 (383.1634)


   

17,22-dihydroxy-16,20-dimethyl-4-oxa-14-azahexacyclo[15.4.1.0²,⁷.0⁸,²¹.0¹²,²⁰.0¹⁴,¹⁹]docosa-1(22),2(7),8(21)-triene-3,9-dione

17,22-dihydroxy-16,20-dimethyl-4-oxa-14-azahexacyclo[15.4.1.0²,⁷.0⁸,²¹.0¹²,²⁰.0¹⁴,¹⁹]docosa-1(22),2(7),8(21)-triene-3,9-dione

C22H25NO5 (383.1733)


   

methyl (1s,2s,3s,5s,10r)-2,6-dimethyl-21-oxo-14-oxa-8-azahexacyclo[11.6.1.1¹,⁵.0²,¹⁰.0³,⁸.0¹⁷,²⁰]henicosa-13(20),17-diene-18-carboxylate

methyl (1s,2s,3s,5s,10r)-2,6-dimethyl-21-oxo-14-oxa-8-azahexacyclo[11.6.1.1¹,⁵.0²,¹⁰.0³,⁸.0¹⁷,²⁰]henicosa-13(20),17-diene-18-carboxylate

C23H29NO4 (383.2096)


   

n-[(4-{[5-(acetyloxy)-3,4-dihydroxy-6-methyloxan-2-yl]oxy}phenyl)methyl]ethoxycarboximidic acid

n-[(4-{[5-(acetyloxy)-3,4-dihydroxy-6-methyloxan-2-yl]oxy}phenyl)methyl]ethoxycarboximidic acid

C18H25NO8 (383.158)


   

3-methoxy-4-(4-methoxyphenyl)-6-(3-methylbut-2-en-1-yl)-3h-quinoline-2,4,5-triol

3-methoxy-4-(4-methoxyphenyl)-6-(3-methylbut-2-en-1-yl)-3h-quinoline-2,4,5-triol

C22H25NO5 (383.1733)


   

(3s,8as)-3-{[(3s)-2,6-dihydroxy-3-(3-methylbut-2-en-1-yl)indol-3-yl]methyl}-1-hydroxy-3h,6h,7h,8h,8ah-pyrrolo[1,2-a]pyrazin-4-one

(3s,8as)-3-{[(3s)-2,6-dihydroxy-3-(3-methylbut-2-en-1-yl)indol-3-yl]methyl}-1-hydroxy-3h,6h,7h,8h,8ah-pyrrolo[1,2-a]pyrazin-4-one

C21H25N3O4 (383.1845)


   

(3r,4r)-3-methoxy-4-(4-methoxyphenyl)-6-(3-methylbut-2-en-1-yl)-3h-quinoline-2,4,5-triol

(3r,4r)-3-methoxy-4-(4-methoxyphenyl)-6-(3-methylbut-2-en-1-yl)-3h-quinoline-2,4,5-triol

C22H25NO5 (383.1733)


   

{5,9,9-trimethyl-19-oxo-4,10-dioxa-18-azapentacyclo[9.8.0.0²,⁸.0³,⁵.0¹²,¹⁷]nonadeca-1(11),12,14,16-tetraen-18-yl}methyl acetate

{5,9,9-trimethyl-19-oxo-4,10-dioxa-18-azapentacyclo[9.8.0.0²,⁸.0³,⁵.0¹²,¹⁷]nonadeca-1(11),12,14,16-tetraen-18-yl}methyl acetate

C22H25NO5 (383.1733)


   

(3r)-3-[(1s)-2-[(1s,4r,4as,7s,8ar)-7-chloro-4-hydroxy-5,5,8a-trimethyl-2-methylidene-hexahydro-1h-naphthalen-1-yl]-1-hydroxyethyl]-5-hydroxy-3,4-dihydropyrrol-2-one

(3r)-3-[(1s)-2-[(1s,4r,4as,7s,8ar)-7-chloro-4-hydroxy-5,5,8a-trimethyl-2-methylidene-hexahydro-1h-naphthalen-1-yl]-1-hydroxyethyl]-5-hydroxy-3,4-dihydropyrrol-2-one

C20H30ClNO4 (383.1863)


   

[(2s,3s,5r,8s)-5,9,9-trimethyl-19-oxo-4,10-dioxa-18-azapentacyclo[9.8.0.0²,⁸.0³,⁵.0¹²,¹⁷]nonadeca-1(11),12,14,16-tetraen-18-yl]methyl acetate

[(2s,3s,5r,8s)-5,9,9-trimethyl-19-oxo-4,10-dioxa-18-azapentacyclo[9.8.0.0²,⁸.0³,⁵.0¹²,¹⁷]nonadeca-1(11),12,14,16-tetraen-18-yl]methyl acetate

C22H25NO5 (383.1733)